u䒠LcVdBUC"H^AGPzU=a:4;6^
܍kEy8peJ|3$zόdx8vў>:rmV o.XhjQv;TH+}| q7%+h-x!Nd2=-.Um" ỏ.
ǭԂ_c˝Ns^,/ǯޅC;@z~/fQa
m[D2jj7+wK"_S|z\aw#T}
,XVG?tD33t,s3+i,.p
o/8ZL\|:2ݮ^rx<\GY'"%6'lLS0̈́Yp-M
bF? SoqNOc#n @?c&ɡPrpnxm&-DAxz5^GCUA֠F./O~|p[Y[4씌Gx*<:H]VYj6~fZVM]4[MYP\g̷M7dV d
endstream
endobj
35 0 obj
<>stream
hTPMo +|!RUB>tSp2 B3!Oq6n1Bg 8sWQ:nj
N^irP+RefQc:a!s1)oVVHUUbcZ"]涏CU]ۅ Sb|I
endstream
endobj
37 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
10.4607 0 0 10.4607 59.7543 698.2297 Tm
0 0 0 rg
0 Tc
0 Tw
[(Pre-Clinical)-303.7(Studies)]TJ
/F6 1 Tf
10.959 0 0 10.959 59.7543 685.2471 Tm
[(The)-249.6(anxiolytic)-241.4(effects)-245.8(of)-248.8(CBD)-246.1(were)-242.8(initially)-246.3(explored)-244.9(in)]TJ
0 -1.1795 TD
[(pre-clinical)-404.7(studies,)-408.9(using)-402.2(several)-404.1(animal)-403.2(models)-402.3(and)]TJ
0 -1.1847 TD
[(behavioral)-446(tests.)-444.7(The)-441(elevated)-442.5(plus-maze)-447.9(\(EPM\))-440(was)]TJ
0 -1.1795 TD
[(one)-286.4(of)-279.9(the)-282.3(rst)-285.8(tests)-279.9(used)-285.5(in)-280.2(rodents)-283.2(to)-284.4(study)-282.9(the)-282.3(anxi-)]TJ
0 -1.1847 TD
[(olytic)-271.3(effects)-271.7(of)-264.3(CBD.)-271.3(Guimara)]TJ
11.8569 .0103 TD
()Tj
.419 -.0103 TD
[(es)-265(et)-270.1(al.)]TJ
8.2191 0 0 7.3052 226.4881 638.3054 Tm
(44)Tj
10.959 0 0 10.959 237.3165 633.4297 Tm
[(used)-270(the)-271.9(EPM)]TJ
-16.2024 -1.1795 TD
-.0001 Tc
[(to)-253.4(demonstrate)-256.2(a)-251.1(full)-256.6(doseresponse)-256.6(curve)-252.3(in)-254.4(rats,)-255.1(after)]TJ
T*
0 Tc
[(acute)-216.3(systemic)-208.6(administration)-209.6(of)-212.6(CBD,)-209.2(which)-213(produced)]TJ
0 -1.1847 TD
-.0001 Tc
[(a)-463.2()47.2(bell-shaped)43.1()-459.8(doseresponse)-463.5(curve.)-458.5(These)-457.8(ndings)]TJ
0 -1.1795 TD
0 Tc
[(indicated)-275.2(that)-274.8(CBD)-272(is)-271(anxiolytic)-272.5(at)-274.9(low)-269.8(and)-271.2(intermedi-)]TJ
0 -1.1847 TD
[(ate)-221.1(doses)-215.7(and)-219.5(produces)-213.4(anxiogenic-like)-219.5(effects)-214.8(at)-218(higher)]TJ
0 -1.1795 TD
[(doses.)-240.8(This)-243.4(has)-240.7(been)-237.7(further)-243.5(conrmed)-240.3(in)-238.8(other)-240.8(animal)]TJ
0 -1.1847 TD
[(models)-293.7(of)-290.2(innate)-291.4(fear)-292.3(and)-291.9(anxiety-like)-289.4(behaviors)-293.1(using)]TJ
0 -1.1795 TD
[(various)-351(behavioral)-342.5(tests,)-346.4(such)-346.9(as)-347.5(the)-349.5(EPM,)-344.1(open)-351(eld,)]TJ
0 -1.1847 TD
[(lightdark)-271.1(test,)-265.5(and)-271.2(predator)-265.5(exposure.)]TJ
8.2191 0 0 7.3052 229.6629 521.7448 Tm
(25)Tj
10.959 0 0 10.959 240.4913 516.8691 Tm
(Furthermore,)Tj
-16.4921 -1.1795 TD
[(using)-278.1(the)-271.9(EPM,)-276.8(CBD)-272(displays)-277.5(anxiolytic)-272.5(effects)-276.8(similar)]TJ
0 -1.1847 TD
[(to)-356.8(diazepam)-351.6(in)-352.6(both)-355.3(mice)-351.5(and)-354(rats.)]TJ
8.2191 0 0 7.3052 218.2676 495.8361 Tm
(44,45)Tj
10.959 0 0 10.959 239.6976 490.9605 Tm
[(Other)-353.6(behav-)]TJ
-16.4196 -1.1795 TD
[(ioral)-320.4(tests)-316.1(used)-316.5(include)-320.6(the)-313.3(Vogal)-317(test,)-317.3(classical)-318.6(condi-)]TJ
T*
[(tioning,)-556.8(marble)-552.6(burying)-551.3(test,)-555.2(chronic)-551.9(unpredictable)]TJ
0 -1.1847 TD
[(stress)-236.7(test,)-234.5(fear)-235.4(and)-235(predator)-234.5(exposure)-234.3(tests,)-237.8(and)-235(the)-235.7(so-)]TJ
0 -1.1795 TD
[(cial)-230.4(interaction)-223.8(test,)-229.3(which)-228.5(have)-227.3(demonstrated)-222.4(different)]TJ
0 -1.1847 TD
[(ndings,)-421.1(including)-414(anxiolytic,)-416.6(antistress,)-413.5(anticompul-)]TJ
0 -1.1795 TD
[(sive,)-317.1(and)-317.8(panicolytic-like)-316.9(effects)-318.2(in)-316.4(rodents)-314.2(\(for)-317.8(recent)]TJ
0 -1.1847 TD
[(reviews,)-277.5(see)-278.4(Blessing)-276.6(et)-280.4(al.,)]TJ
8.2191 0 0 7.3052 175.4645 405.1841 Tm
(3)Tj
10.959 0 0 10.959 182.4377 400.3086 Tm
[(Lee)-276.9(et)-280.4(al.,)]TJ
8.2191 0 0 7.3052 223.6535 405.1841 Tm
(8)Tj
10.959 0 0 10.959 230.6267 400.3086 Tm
[(and)-276.4(Papagianni)]TJ
-15.5919 -1.1795 TD
[(and)-302.3(Stevenson)]TJ
8.2191 0 0 7.3052 123.3637 392.2581 Tm
(25)Tj
10.959 0 0 10.959 131.244 387.3826 Tm
(\).)Tj
-5.5198 -1.1847 TD
[(To)-743.2(examine)-742(the)-747.9(mechanism)-744.6(of)-740.3(CBD-mediated)]TJ
-1.0036 -1.1795 TD
[(anxiolytic-like)-303.7(effects)-307.9(in)-300.9(animals,)-307.4(microinjection)-297.5(mod-)]TJ
T*
[(els)-413.3(have)-408.4(been)-413.6(utilized.)-412.7(When)-410(CBD)-406.5(was)-410.2(injected)-412.3(into)]TJ
0 -1.1847 TD
[(specic)-206.8(brain)-210.4(regions)-206.1(associated)-205.4(with)-206.2(anxiety,)-205.7(including)]TJ
0 -1.1795 TD
[(the)-339.2(central)-341.7(nucleus)-340.8(of)-336.8(the)-339.2(amygdala,)-339.2(the)-339.2(dorsal)-337.9(peria-)]TJ
0 -1.1847 TD
[(queductal)-278.6(gray,)-279.1(and)-281.6(the)-277.1(bed)-276.3(nucleus)-283.9(of)-274.7(the)-282.3(stria)-275(termi-)]TJ
0 -1.1795 TD
[(nalis,)-242.4(anxiolytic)-241.4(effects)-240.6(were)-237.7(produced.)]TJ
8.2191 0 0 7.3052 227.2818 301.6062 Tm
(3)Tj
10.959 0 0 10.959 233.8582 296.7307 Tm
[(Antagonism)-240.2(of)]TJ
-15.8868 -1.1847 TD
[(the)-292.6(5-HT1A)-289.6(receptor)-292.2(resulted)-293.4(in)-290.5(attenuation)-289.3(of)-290.2(anxio-)]TJ
0 -1.1795 TD
[(lytic)-321.2(effects,)-317.5(thereby)-318.7(potentially)-321.6(mediated)-315.9(some)-318.7(symp-)]TJ
0 -1.1847 TD
[(toms)-836.2(of)-833.4(anxiety.)]TJ
8.2191 0 0 7.3052 142.3559 262.7149 Tm
(26)Tj
10.959 0 0 10.959 159.4204 257.8393 Tm
[(Overall,)-830.7(pre-clinical)-834.1(evidence)]TJ
-9.0944 -1.1795 TD
[(strongly)-270.5(supports)-275.9(the)-271.9(anxiolytic)-267.3(role)-275.5(of)-269.5(CBD;)-271.3(however,)]TJ
0 -1.1847 TD
[(the)-230.5(majority)-227.9(of)-233.3(pre-clinical)-228.8(research)-230.5(has)-230.3(only)-227.2(been)-232.5(con-)]TJ
0 -1.1795 TD
[(ducted)-451.3(using)-448.8(male)-444(animals,)-447.1(therefore,)-449.9(these)-443.8(ndings)]TJ
T*
[(need)-300.4(to)-299.9(be)-299.7(replicated)-299.7(using)-298.8(females.)]TJ
8.2191 0 0 7.3052 217.1338 210.8976 Tm
(3,8)Tj
/F4 1 Tf
10.4607 0 0 10.4607 59.7543 180.17 Tm
[(Clinical)-305.1(Studies)]TJ
/F6 1 Tf
10.959 0 0 10.959 59.7543 167.1874 Tm
[(The)-228.9(anxiolytic)-231.1(effects)-230.3(of)-228.1(CBD)-225.4(observed)-228.1(in)-228.5(animals)-230.6(have)]TJ
T*
[(provided)-290.9(insight)-284.5(and)-286.8(guided)-285.8(human)-288.8(research.)-286.7(The)-285.8(ini-)]TJ
0 -1.1847 TD
[(tial)-406.4(clinical)-408.4(studies)-409.7(examining)-406(the)-406.4(effects)-406.2(of)-409.2(CBD)-406.5(on)]TJ
0 -1.1795 TD
[(anxiety)-227.1(were)-222.2(performed)-220.1(in)-223.3(the)-225.4(1980s,)-223.1(when)-219.9(it)-224.3(was)-224(dem-)]TJ
0 -1.1847 TD
[(onstrated)-232.2(that)-228.3(CBD)-230.6(could)-230.6(attenuate)-227.6(the)-230.5(anxiogenic)-229.6(and)]TJ
0 -1.1795 TD
[(psychoactive)-291.8(effects)-292.4(of)-290.2(THC)-292.8(in)-290.5(healthy)-292.7(volunteers.)]TJ
8.2191 0 0 7.3052 281.3102 107.3197 Tm
(46,47)Tj
10.959 0 0 10.959 59.7543 89.5181 Tm
[(Since)-340.8(then,)-335.5(studies)-337.2(in)-337.1(healthy)-334.1(volunteers)]TJ
8.2191 0 0 7.3052 239.4708 94.337 Tm
(14,46,4850)Tj
10.959 0 0 10.959 282.444 89.5181 Tm
(and)Tj
-20.3202 -1.1847 TD
[(individuals)-369.4(with)-361.4(SAD)]TJ
8.2191 0 0 7.3052 155.9055 81.411 Tm
(15,28)Tj
10.959 0 0 10.959 177.5054 76.5354 Tm
[(provide)-366(early)-366.7(evidence)-364.5(that)]TJ
-10.7447 -1.1795 TD
[(CBD)-282.3(may)-274.3(have)-284.2(anxiolytic)-277.6(effects)-276.8(in)-280.2(humans.)-281(The)-280.7(Sim-)]TJ
22.912 57.8774 TD
[(ulation)-252.6(Public)-254.5(Speaking)-254.7(Test)-254.3(has)-256.2(been)-253.2(used)-259.6(to)-253.3(examine)]TJ
0 -1.1847 TD
[(the)-209.8(effects)-209.6(of)-207.4(CBD)-209.9(on)-205.7(anxiety)-211.6(in)-207.8(clinical)-206.7(studies.)-212.4(In)-207.2(both)]TJ
0 -1.1795 TD
[(healthy)-613.5(volunteers)-618(and)-617.8(individuals)-617.7(diagnosed)-619.2(with)]TJ
0 -1.1847 TD
[(SAD,)-241.5(it)-239.8(was)-239.5(found)-240.5(that)-238.6(in)-238.8(comparison)-242(with)-237.2(the)-240.9(placebo)]TJ
0 -1.1795 TD
[(group,)-218.7(a)-220(400)-213.3(or)-222.4(600)-161.5(mg)-219.9(single)-220(dose)-217.6(of)-217.8(CBD)-215.1(signicantly)]TJ
0 -1.1847 TD
[(reduced)-263(subjective)-262.5(symptoms)-260.1(of)-259.2(anxiety)-263.3(and)-260.9(decreased)]TJ
0 -1.1795 TD
[(cognitive)-201.7(impairment)-206.1(and)-204(speech)-203(performance)-204.9(discom-)]TJ
T*
(fort.)Tj
8.2191 0 0 7.3052 329.2157 612.0565 Tm
(15,28)Tj
10.959 0 0 10.959 350.2487 607.2377 Tm
[(Neuroimaging)-313.6(studies)]TJ
8.2191 0 0 7.3052 446.9668 612.0565 Tm
(28,48,49,51,52)Tj
10.959 0 0 10.959 497.0266 607.2377 Tm
[(of)-316.1(acute)-319.7(ad-)]TJ
-16.9887 -1.1847 TD
[(ministration)-644.1(of)-642(CBD)-644.5(have)-646.3(demonstrated)-641.5(modied)]TJ
0 -1.1795 TD
[(blood)-327(ow)-325.1(in)-326.8(specic)-331(brain)-329.4(structures)-330.7(associated)-324.3(with)]TJ
0 -1.1847 TD
[(anxiety,)-428.1(including)-424.3(the)-427.1(amygdala,)-427.2(hypothalamus,)-421(hip-)]TJ
0 -1.1795 TD
[(pocampus,)-524.8(and)-519.6(cingulate)-523.1(cortex.)]TJ
8.2191 0 0 7.3052 460.5164 560.2959 Tm
(53)Tj
10.959 0 0 10.959 474.1227 555.4203 Tm
[(In)-527.9(addition,)-523.7(ret-)]TJ
-14.8987 -1.1847 TD
[(rospective)-386.4(studies)-383.8(have)-387.7(found)-385.3(CBD)-385.8(to)-387.8(be)-382.5(effective)-386.3(in)]TJ
0 -1.1795 TD
[(reducing)-452.2(anxiety)-454.7(symptoms)-446.3(in)-456.1(patients)-453.4(with)-449.3(anxiety)]TJ
0 -1.1847 TD
[(disorders)-502.8(and)-504(PTSD.)-507.8(These)-504.3(studies)-502.8(examined)-506.5(vary-)]TJ
0 -1.1795 TD
[(ing)-365.4(doses)-360.5(\(e.g.,)-369(2575)-160.6(mg/day\))-364.4(and)-369.5(preparation)5.1(s)-365.4(\(e.g.,)]TJ
T*
[(oral,)-295.1(sublingual)-297.2(spray\))-297.2(of)-300.5(CBD)-292.7(across)-296.8(different)-297.9(patient)]TJ
0 -1.1847 TD
[(populations)-386.8(and)-395.4(in)-388.8(combination)-388.8(with)-387.2(other)-390.8(forms)-390.1(of)]TJ
0 -1.1795 TD
[(pharmacologica)6(l)-593.2(and)-586.8(psychotherapies,)]TJ
8.2191 0 0 7.3052 484.8376 469.644 Tm
(5456)Tj
10.959 0 0 10.959 511.3133 464.7684 Tm
(although)Tj
-18.2923 -1.1847 TD
[(ndings)-375.2(from)-371.3(such)-378(retrospective)-370.1(studies)-378.6(provide)-371.2(lim-)]TJ
0 -1.1795 TD
[(ited)-426.4(data)-430.2(due)-427(to)-429.2(small)-427.1(sample)-429.1(sizes)-430.4(and)-431.6(lack)-425.6(proper)]TJ
0 -1.1847 TD
(controls.)Tj
.9984 -1.1795 TD
[(Three)-235.3(ongoing)-233.9(clinical)-237.7(trials)-237.1(are)-231.5(currently)-238.6(investigat-)]TJ
-.9984 -1.1847 TD
[(ing)-241.2(the)-246.1(effects)-245.8(of)-243.6(CBD)-246.1(as)-244(a)-240.7(potential)-243.3(treatment)-246.6(for)-241.8(anx-)]TJ
0 -1.1795 TD
[(iety)-266(disorders.)]TJ
8.2191 0 0 7.3052 372.1322 391.918 Tm
(5759)Tj
10.959 0 0 10.959 395.0361 387.0424 Tm
[(Van)-265(der)-267.5(Flier)-264.5(et)-270.1(al.)]TJ
8.2191 0 0 7.3052 476.9573 391.918 Tm
(57)Tj
10.959 0 0 10.959 487.729 387.0424 Tm
[(are)-267.7(examining)]TJ
-16.1403 -1.1847 TD
[(the)-297.8(effects)-302.7(of)-295.4(a)-302.8(weekly)-299.6(dose)-300.3(of)-295.4(300)-166.7(mg)-297.5(of)-300.5(CBD)-297.9(admin-)]TJ
0 -1.1795 TD
[(istered)-379.2(orally)-374.2(for)-376.3(8)-374.6(weeks,)-379.1(in)-378.5(individuals)-379.7(with)-371.7(phobic)]TJ
T*
[(disorders.)-233.1(An)-230.8(ongoing)-228.8(phase)-230.7(3)-234.9(clinical)-227.4(trial)-233.8(is)-229.6(exploring)]TJ
0 -1.1847 TD
[(the)-215(use)-215.7(of)-212.6(200)-166.7(mg)-214.7(ranging)-215.7(up)-217.1(to)-211.9(800)-166.7(mg)-214.7(of)-212.6(CBD)-215.1(admin-)]TJ
0 -1.1795 TD
[(istered)-260.2(in)-259.5(oil)-257.4(capsules,)-261.1(for)-257.3(the)-256.4(treatment)-262.1(of)-259.2(GAD,)-255(SAD,)]TJ
0 -1.1847 TD
[(panic)-474.7(disorder,)-478.1(and)-473(agoraphobia.)]TJ
8.2191 0 0 7.3052 461.877 314.192 Tm
(58)Tj
10.959 0 0 10.959 474.9731 309.3164 Tm
[(Finally,)-475.2(an)-475.7(open)]TJ
-14.9763 -1.1795 TD
[(label)-221.5(phase)-225.5(2)-224.6(clinical)-222.2(trial)-223.5(is)-224.4(currently)-228.2(examining)-219.8(the)-225.4(ef-)]TJ
0 -1.1847 TD
[(fects)-342.4(of)-336.8(a)-344.1(sublingual,)-337.9(1.0)-163.9(mg)-344(CBD)-339.3(tincture)-339.9(\(10)-163(mg/mL)]TJ
0 -1.1795 TD
[(of)-450.6(CBD\))-451.5(three)-454.1(times)-448.1(a)-452.8(day)-452.5(for)-453.9(4)-452.2(weeks,)-451.5(in)-456.1(patients)]TJ
0 -1.1847 TD
[(with)-521.7(an)-527.4(anxiety)-522(disorder)-525.4(diagnosis.)]TJ
8.2191 0 0 7.3052 474.803 262.3748 Tm
(59)Tj
10.959 0 0 10.959 488.4093 257.4991 Tm
[(These)-525(studies)]TJ
-16.2024 -1.1795 TD
[(are)-252.2(of)-254(great)-252.7(importance)-253.5(because)-252.2(the)-256.4(majority)-248.6(of)-254(studies)]TJ
T*
[(assessing)-224(the)-225.4(effects)-225.1(of)-228.1(CBD)-220.3(on)-226.4(anxiety)-221.9(were)-227.3(conducted)]TJ
0 -1.1847 TD
[(in)-352.6(healthy)-349.7(volunteers,)-353.5(and)-348.8(the)-354.7(clinical)-351.5(trials)-350.9(involving)]TJ
0 -1.1795 TD
[(patients)-272.3(with)-273.4(SAD)-268.1(used)-275.2(small)-271.9(sample)-273.9(sizes,)-274.4(did)-272.7(not)-271(in-)]TJ
0 -1.1847 TD
[(clude)-247.3(placebo)-246(controls)-244.6(and)-250.5(did)-246.8(not)-245.2(establish)-243.8(a)-251(dosere-)]TJ
0 -1.1795 TD
[(sponse)-440.3(relationship)-443.8(between)-446.4(CBD)-442.7(plasma)-439.1(levels)-448.1(and)]TJ
0 -1.1847 TD
[(anxiety)-325.4(symptom)-318.8(measurements.)]TJ
8.2191 0 0 7.3052 456.3778 171.7228 Tm
(60)Tj
10.959 0 0 10.959 467.7731 166.8472 Tm
[(In)-326.2(addition,)-327.1(future)]TJ
-14.3193 -1.1795 TD
[(clinical)-377.4(trials)-382(are)-381.5(warranted)-380.6(to)-382.7(examine)-379.9(the)-380.6(effects)-380.3(of)]TJ
0 -1.1847 TD
[(CBD)-634.1(on)-635.1(other)-634(anxiety)-641(disorders,)-636.6(including)-636.4(GAD,)]TJ
0 -1.1795 TD
[(panic)-241.9(disorder,)-240.1(and)-245.4(phobic)-242.4(disorder,)-240.1(as)-244(well)-238.3(as)-244(anxiety-)]TJ
0 -1.1847 TD
[(related)-300.6(conditions,)-296(such)-300.4(as)-300.9(PTSD)-296.4(and)-302.3(OCD.)]TJ
/F4 1 Tf
10.4607 0 0 10.4607 310.8472 89.1779 Tm
[(Sex)-297.9(Differences)-301.6(in)-301.4(Anxiety)-300.4(and)-298.4(the)-299.8(Utility)-305.4(of)-298.1(CBD)]TJ
/F6 1 Tf
10.959 0 0 10.959 310.8472 76.1953 Tm
[(The)-306.5(prevalence)-308.1(rates)-305.3(of)-310.9(anxiety)-304.7(disorders)-311.4(are)-309.1(approxi-)]TJ
0 -1.1795 TD
[(mately)-366.9(doubled)-374.6(in)-368.1(females)-371.4(compared)-376(with)-366.5(males)-374.9(and)]TJ
/F4 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(U)-5.9(S)0(E)-298(O)0(F)-308.4(CANNA)-9.3(BIDIOL)-308.8(FOR)-300.2(THE)-306.7(TREAT)-9.9(MENT)-305.8(OF)-302.8(ANXI)-8(ETY)-21973.5(193)]TJ
ET
endstream
endobj
41 0 obj
<>stream
/GS1 gs
BT
/F6 1 Tf
10.959 0 0 10.959 62.022 697.8896 Tm
0 0 0 rg
0 Tc
0 Tw
[(there)-221.4(are)-226.3(differing)-225.4(symptoms)-218.7(between)-223.9(sexes.)]TJ
8.2191 0 0 7.3052 252.7936 702.7651 Tm
(2,61,62)Tj
10.959 0 0 10.959 278.5322 697.8896 Tm
(After)Tj
-19.7563 -1.1847 TD
[(puberty,)-669.9(females)-676.6(are)-671.2(more)-670.5(prone)-669.8(to)-672.4(anxiety)-672(dis-)]TJ
0 -1.1795 TD
[(orders)-467.3(compared)-469.2(with)-464.8(males,)-472.4(largely)-465.8(due)-468.4(to)-465.4(the)-468.5(in-)]TJ
0 -1.1847 TD
[(volvement)-539.1(of)-543.7(sex)-541.9(chromosomes)-535.8(and)-540.2(hormones.)]TJ
8.2191 0 0 7.3052 283.5779 663.8738 Tm
(63,64)Tj
10.959 0 0 10.959 62.022 646.0723 Tm
[(Females)-328.7(typically)-327.2(demonstrate)-328.6(increased)-332.2(symptom)-324(se-)]TJ
T*
[(verity,)-369.3(comorbidity,)-363.3(and)-369.5(burden)-367.1(of)-362.6(illness.)]TJ
8.2191 0 0 7.3052 250.8661 637.9652 Tm
(65)Tj
10.959 0 0 10.959 262.7716 633.0896 Tm
[(In)-367.6(terms)]TJ
-18.3182 -1.1795 TD
[(of)-341.9(symptomology,)-340.4(females)-340.4(more)-339.4(frequently)-344.8(report)-337.9(so-)]TJ
T*
[(matic)-230.3(discomfort,)-227.9(demonstrate)-230.3(more)-225.6(internalizing)-230.7(cop-)]TJ
0 -1.1847 TD
[(ing)-696.5(styles,)-690.5(rumination,)-697.6(and)-690.3(have)-698(higher)-694(rates)-693.3(of)]TJ
0 -1.1795 TD
[(comorbid)-390.7(mood)-389.1(disorders.)]TJ
8.2191 0 0 7.3052 181.1905 586.2046 Tm
(61,66)Tj
10.959 0 0 10.959 203.0173 581.329 Tm
[(Males)-389.8(are)-391.9(more)-386(likely)]TJ
-12.8657 -1.1847 TD
[(to)-299.9(report)-301.7(strained)-303.4(relationships)-302.2(as)-300.9(a)-302.8(result)-303.4(of)-300.5(excessive)]TJ
0 -1.1795 TD
-.0001 Tc
[(worry,)-357.5(have)-361.9(an)-362(increased)-358.1(fear)-359.6(of)-362.7(social)-359.7(consequences,)]TJ
0 -1.1847 TD
0 Tc
[(and)-498.9(are)-500.5(more)-499.8(likely)-499.8(to)-496.5(have)-501.5(comorbid)-494.2(alcohol)-499.3(and)]TJ
0 -1.1795 TD
[(substance)-464.8(abuse.)]TJ
8.2191 0 0 7.3052 136.3464 534.3873 Tm
(61,66)Tj
10.959 0 0 10.959 159.0236 529.5117 Tm
[(However,)-464.1(symptomolog)7.9(y)-468(varies)]TJ
-8.8513 -1.1847 TD
[(between)-203.2(different)-199.6(anxiety)-206.4(disorders,)-202(is)-203.7(inuenced)-200(by)-200.8(so-)]TJ
0 -1.1795 TD
[(cial)-411.4(and)-410.9(environmental)-406.1(factors,)-413.7(and)-410.9(is)-410.6(dependent)-407(on)]TJ
T*
[(puberty,)-266.4(menstrual)-261.9(cycle)-263.3(phase,)-266.2(pregnancy,)-261(and)-266.1(meno-)]TJ
0 -1.1847 TD
[(pause)-314.1(in)-311.2(females.)]TJ
8.2191 0 0 7.3052 137.4803 482.5699 Tm
(61,67)Tj
10.959 0 0 10.959 158.5133 477.6943 Tm
[(Males)-307(and)-312.6(females)-314.5(may)-310.6(respond)]TJ
-8.8047 -1.1795 TD
[(differently)-355.5(to)-356.8(psychotropic)-353.3(medication)]TJ
8.2191 0 0 7.3052 232.8944 469.644 Tm
(6769)Tj
10.959 0 0 10.959 252.8503 464.7684 Tm
[(;)-356.2(thus,)-351.6(it)-358.8(is)]TJ
-17.4129 -1.1847 TD
[(important)-245.4(to)-248.2(understand)-244.7(sex)-247.1(differences)-252.3(in)-244(anxiety)-247.8(dis-)]TJ
0 -1.1795 TD
[(orders)-260.4(to)-263.7(better)-260.7(develop)-261.9(treatments)-260.2(for)-262.5(both)-257(males)-261.1(and)]TJ
0 -1.1847 TD
(females.)Tj
.9984 -1.1795 TD
[(It)-415.2(has)-411.4(been)-408.4(demonstrated)-413.8(in)-409.5(animals)-411.6(and)-410.9(humans)]TJ
-.9984 -1.1847 TD
[(that)-549(THC)-551.4(has)-545.9(differential)-551.1(effects)-551(in)-554.4(males)-545.6(and)-550.6(fe-)]TJ
0 -1.1795 TD
(males.)Tj
8.2191 0 0 7.3052 89.4047 391.918 Tm
(70)Tj
10.959 0 0 10.959 103.011 387.0424 Tm
[(Sex)-520.7(differences)-521.3(have)-522.2(been)-522.2(observed)-523(in)-518.2(the)]TJ
-3.7402 -1.1847 TD
(pharmacokinetics,)Tj
8.2191 0 0 7.3052 141.8456 378.9353 Tm
(7174)Tj
10.959 0 0 10.959 167.9243 374.0597 Tm
[(pharmacodyn)5.8(amics,)]TJ
8.2191 0 0 7.3052 256.0251 378.9353 Tm
(7578)Tj
10.959 0 0 10.959 282.1039 374.0597 Tm
(sub-)Tj
-20.0823 -1.1795 TD
[(jective)-306.6(effects,)]TJ
8.2191 0 0 7.3052 122.7401 366.0094 Tm
(7982)Tj
10.959 0 0 10.959 146.0409 361.1338 Tm
[(abuse)-303.1(liability,)]TJ
8.2191 0 0 7.3052 208.9133 366.0094 Tm
(8386)Tj
10.959 0 0 10.959 232.2141 361.1338 Tm
[(and)-307.5(therapeutic)]TJ
-15.5299 -1.1795 TD
[(potential)-408.8(of)-409.2(THC)-406.6(\(for)-410.9(recent)-411(review)-409.5(see)-412.9(Cooper)-406.6(and)]TJ
0 -1.1847 TD
(Craft)Tj
8.2191 0 0 7.3052 84.4724 340.1007 Tm
(70)Tj
10.959 0 0 10.959 92.3527 335.2251 Tm
[(\).)-261.5(Thus,)-256.8(other)-261.5(agents)-254.9(that)-259.3(target)-255.9(the)-261.6(endocanna-)]TJ
-2.7676 -1.1795 TD
[(binoid)-233.2(system,)-232(such)-233.1(as)-233.6(CBD,)-229.9(might)-228.8(be)-232.5(expected)-235.2(to)-232.6(have)]TJ
0 -1.1847 TD
[(similar)-227.6(sex-dependent)-232.8(effects.)-229.6(The)-228.9(pharmacokinetics)-229.3(of)]TJ
0 -1.1795 TD
[(CBD)-380.6(differ)-377.4(between)-379.1(males)-380(and)-379.9(females)]TJ
8.2191 0 0 7.3052 237.77 301.2661 Tm
(71,87)Tj
10.959 0 0 10.959 255.3448 296.3904 Tm
[(;)-382.1(however,)]TJ
-17.6405 -1.1847 TD
[(there)-536.9(are)-541.9(nearly)-534.5(no)-542(sex)-536.8(comparisons)-540.1(of)-538.5(its)-538(effects,)]TJ
0 -1.1795 TD
[(even)-290(in)-285.4(animals.)]TJ
8.2191 0 0 7.3052 133.5118 275.3574 Tm
(70)Tj
10.959 0 0 10.959 144.5669 270.4818 Tm
[(The)-285.8(majority)-284.8(of)-285(current)-289.6(pre-clinical)]TJ
-7.5321 -1.1847 TD
[(studies)-476.9(have)-470.4(solely)-472.8(been)-475.6(conducted)-473.9(using)-474.6(male)-475(ani-)]TJ
0 -1.1795 TD
(mals,)Tj
8.2191 0 0 7.3052 84.8126 249.4488 Tm
(8)Tj
10.959 0 0 10.959 92.863 244.5731 Tm
[(and)-369.5(to)-372.3(our)-369.7(knowledge)-368.2(no)-371.3(clinical)-372.2(studies)-368.3(have)]TJ
-2.8142 -1.1795 TD
[(yet)-401.8(to)-398.2(explore)-397.6(sex)-397.1(and/or)-399.2(gender)-399.3(differences)-402.3(in)-399.2(CBD)]TJ
0 -1.1847 TD
[(as)-476.8(a)-473.5(potential)-470.9(treatment)-474.2(for)-474.6(anxiety.)-474.7(Of)-475.4(the)-473.7(clinical)]TJ
0 -1.1795 TD
[(studies)-337.2(that)-336.9(did)-334.7(include)-341.3(females,)]TJ
8.2191 0 0 7.3052 205.5117 210.6141 Tm
(14,15,46)Tj
10.959 0 0 10.959 236.4661 205.7385 Tm
[(no)-335.1(sex-specic)]TJ
-15.9179 -1.1847 TD
[(analyses)-209.4(were)-211.8(performed.)-209(Therefore,)-210.3(due)-209.8(to)-206.8(the)-209.8(increas-)]TJ
0 -1.1795 TD
[(ing)-365.4(prevalence)-365(of)-362.6(anxiety)-366.8(disorders)-363.1(and)-364.4(lack)-363.5(of)-362.6(effec-)]TJ
0 -1.1847 TD
[(tiveness)-329.5(of)-331.6(current)-331(treatments,)-331.9(it)-327.8(is)-333(crucial)-327.1(to)-330.9(conduct)]TJ
0 -1.1795 TD
[(research)-603(studies)-601.1(examining)-602.6(sex)-604(and)-602.3(gender)-601(differ-)]TJ
0 -1.1847 TD
[(ences)-211.2(in)-212.9(use)-210.6(of)-212.6(CBD)-209.9(as)-212.9(a)-209.6(potential)-212.3(treatment)-210.4(for)-210.7(anxiety)]TJ
0 -1.1795 TD
(disorders.)Tj
/F4 1 Tf
10.4607 0 0 10.4607 62.022 102.1039 Tm
(Conclusions)Tj
/F6 1 Tf
10.959 0 0 10.959 62.022 89.1779 Tm
.0143 Tc
[(Over)-4.5(all,)-538.5(existing)-536.5(pre)-4.2(-)1(cli)-5.1(n)1.8(ic)-4.2(al)-532.4(and)-536.5(c).9(li)-5(nic)-4.2(a)1.2(l)-532.4(e)-4.2(vidence)]TJ
0 -1.1847 TD
.0132 Tc
[(su)-4.8(pp)-4.8(ort)-5.5(s)-238.4(a)-243(p)-4.8(os)-5.6(sibl)-5.8(e)-238.1(r)-5.6(ole)-243.3(f)-1(o)-4.1(r)-243.6(CBD)-240.7(a).1(s)-243.6(a)-243(n)-4.5(o)1.1(ve)-5.3(l)-238.6(t)-5.5(rea)-5(t)-.4(ment)]TJ
0 -1.1795 TD
.0177 Tc
[(for)-378.8(a)-.5(n)5.2(x)4.6(ie)4.3(t)4.1(y)-383(d)4.9(i)3.5(so)5.6(r)4.1(d)-.3(e)4.3(r)4.1(s.)-379.9(T)5.7(h).3(e)-378.5().3(n)5.2(d)-.3(in)5.2(gs)-378.8(re)4.3(v)4.9(i)3.5(ew)6.7(ed)-378(in)-377.6(t)4.1(h).3(is)]TJ
22.9068 57.9085 TD
.0139 Tc
[(s)-4.9(t).3(udy)-355.8(d)1.1(emonst)-4.8(rate)-356.4(the)-356.4(p)1.1(ot)-4.8(ent)-4.8(i)-.3(al)-356.9(of)-357.3(CBD)-353.8(t).3(o)-355.2(p)1.1(r)-4.9(o)1.8(duce)]TJ
0 -1.1847 TD
.015 Tc
[(anxiolytic-like)-339.8(e)-3.5(ffects)-345.2(i).8(n)-344.1(p)-3(re-clinical)-345.4(m)-.7(odels)-345.2(a)1.9(nd)-344.4(the)]TJ
0 -1.1795 TD
.0143 Tc
[(potential)-418.6(o)-3(f)-418.9(C)-2.2(BD)-420.7(to)-422(induce)-423.3(acute)-423.3(a)1.2(nxiolytic)-423.3(e).9(ff)-5.1(ects)]TJ
0 -1.1847 TD
[(when)-267.1(administ)-4.3(ere)-4.1(d)-262.3(as)-263.1(a)-267.7(s).8(i)-4.9(n)1.9(gl)-4.6(e)-262.8(d)-3.6(ose)-268(i).2(n)-267.1(h)-3(ealt)-4.3(hy)-267.4(volun-)]TJ
0 -1.1795 TD
.0148 Tc
[(t)-3.9(eer)-4(s)-257.5(a)1.7(nd)-256.7(indivi)-4.5(duals)-257.5(with)-256(SAD.)-258.7(Although)-256(these)-257.2()-2.6(nd-)]TJ
0 -1.1847 TD
[(i)-4.5(n)2.3(gs)-242(are)-241.7(p)2(romising,)-238(f).6(uture)-236.5(r)1.2(esearch)-240.5(i).6(s)-236.8(n)-2.9(ecessary)-235.9(t)-3.9(o)-235.3(\(1\))]TJ
0 -1.1795 TD
.0146 Tc
[(determine)-252.3(t)1(he)-252.3(efcacy)-246.5(o)-2.7(f)-247.9(C)-1.9(BD)-249.6(i)-4.8(n)-246.2(other)-247.4(a)-3.6(nxiety)-251.6(di)-4.8(sor)-4.2(-)]TJ
T*
.0155 Tc
[(ders)-427.5(aside)-432.4(f)1.3(rom)-429.6(S)2.4(AD)-429.8(in)-426.4(plac)]TJ
12.4208 0 TD
.0142 Tc
[(ebo-c)-4.3(o)2.1(nt)-4.5(roll)-4.8(ed)-433.2(clinical)]TJ
-12.4208 -1.1847 TD
[(t)-4.6(r).5(ials;)-254.2(\().2(2\))-253.3(est)-4.6(a)1(bl)-4.9(ish)-251.6(t)-4.6(he)-252.8(mos)-4.7(t)-253(eff)-5.3(ect)-4.6(ive)-252.8(r)-4.7(out)-4.6(e)-252.8(of)-253.6(admin-)]TJ
0 -1.1795 TD
.0148 Tc
[(i)-4.5(stration)-308.1(and)-313.6(a)1.7(ppropriate)-309(dos)-4(e)-309(of)-309.8(CBD)-311.5(t)1.2(o)-312.9(b)2.7(e)-314.1(u)2(tili)-4.6(zed)]TJ
0 -1.1847 TD
.0145 Tc
[(i)-4.8(n)-287.7(tr)-4.3(eat)-4.2(m)4(ent;)-290(and)-293.2(\().5(3\))-294.3(det)-4.2(e)1.1(rmine)-288.6(t).9(he)-288.6(long-term)-290.9(s).9(afet)-4.2(y)]TJ
0 -1.1795 TD
.0143 Tc
[(and)-205.5(e)-4.2(fc)-4.2(a)1.2(cy)-205.4(of)-201.7(CBD.)-207.4(Ther)-4.5(e)-200.8(i)-5.1(s)-206.3(a)-200.5(s)-4.5(trong)-205.4(need)-205.5(to)-204.8(develop)]TJ
0 -1.1847 TD
.014 Tc
[(alternative)-392.5(a).9(nd)-392(novel)-387.8(t).4(r)-4.8(e).6(at)-4.7(ments)-387.6(f)-5.4(or)-387.6(anxi)-5.4(ety-rel)-5(a).9(ted)]TJ
0 -1.1795 TD
0 Tc
[(di)14.4(s)12.2(o)0(r)15.6(d)0(e)20.3(r)0(s)14.1(,)-392.4(pa)20.6(rt)19.3(ic)13.8(u)13(l)0(a)14.5(r)12.2(ly)-383.5(fo)20.2(cu)15.2(se)19.5(d)-395.7(o)13.7(n)-395.3(s)0(e)19.5(x)-395.9(a)12.8(n)0(d)-387.5(g)13.1(en)15.5(de)20.4(r)-396.5(d)13(if)13(-)]TJ
0 -1.1847 TD
[(fe)13.8(r)12.2(e)0(n)15.5(c)0(e)19.8(s)0(,)-302.6(a)12.8(s)-313.7(p)13(re)14.4(v)13.1(a)0(l)14.5(e)12.5(nc)15.5(e)-308.2(r)0(a)19.8(t)0(e)14.4(s)12.2(,)-309.7(s)0(y)20.2(m)0(p)18(t)0(o)15.7(m)10.2(ol)20.6(og)16.5(y)13.1(,)-309.7(an)15.8(d)-307.7(m)10.2(ed)15.2(-)]TJ
0 -1.1795 TD
[(ic)13.8(a)12.8(t)0(i)18.8(o)0(n)-614.4(r)12.2(es)14.4(p)13(o)0(n)16.7(s)0(e)-611.6(d)0(i)19.5(f)0(f)12.9(e)12.5(rs)-611.9(be)15.9(t)12.3(w)0(e)17(e)12.5(n)-623(m)10.2(en)-610.5(an)15.8(d)-618.1(w)0(o)18.2(m)10.2(en)15.5(.)]TJ
T*
[(Ow)19.2(in)14.7(g)-230(t)12.3(o)-229.4(t)12.3(he)-222.1(l)12(a)0(c)14.9(k)-230.1(o)13.7(f)-231.5(r)12.2(e)0(s)14.4(e)12.5(ar)14.7(c)12.5(h)-229.5(in)-223.3(f)11.7(e)0(m)17.5(a)0(l)19.7(e)-230.6(a)12.8(n)0(i)14.7(m)10.2(al)19.7(s)-230.9(a)12.8(nd)-222(hu)16.4(-)]TJ
0 -1.1847 TD
[(ma)17.8(ns)15.2(,)-371.7(a)0(n)15.8(d)-375(th)20.8(e)-375.5(k)0(n)16.1(o)0(w)18.2(l)12(ed)20.3(ge)-367.6(ga)15.6(p)-375(o)13.7(n)-374.6(s)0(e)14.4(x)-375.2(a)12.8(n)0(d)-366.8(g)0(e)15.2(n)13.3(de)15.2(r)-375.8(d)13(if)13(-)]TJ
0 -1.1795 TD
[(fe)13.8(r)12.2(e)0(n)15.5(c)0(e)19.8(s)-546.5(in)-538.9(th)15.6(e)-546.2(e)0(f)19(f)0(e)19(c)0(t)14.4(i)11.7(ve)15.2(n)13.3(e)0(s)14.4(s)-546.5(of)-538.5(CB)18.1(D)-543.6(a)0(s)-538.9(a)-545.9(po)16.4(t)12.3(e)0(n)15.5(t)12.3(ia)14.1(l)]TJ
0 -1.1847 TD
[(tr)14.2(e)12.5(a)0(t)14.7(m)10.2(e)12.5(n)0(t)-346.8(f)0(o)15(r)-355.1(a)12.8(n)0(x)15.7(i)11.7(et)14.4(y)13.1(,)-356.2(fu)14.3(t)12.3(u)0(r)14.9(e)-354.8(re)19.5(se)14.4(a)12.8(r)0(c)14.4(h)-353.6(s)12.2(h)0(o)17.1(u)0(l)19.9(d)-359.4(f)11.7(o)0(c)15.9(u)13(s)-355.1(o)0(n)]TJ
0 -1.1795 TD
[(th)15.6(i)11.7(s)-293(ar)19.8(ea)14.9(.)]TJ
/F4 1 Tf
10.4607 0 0 10.4607 313.0582 413.9149 Tm
[(Author)-303.3(Disclosure)-299.8(Statement)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 400.9889 Tm
[(The)-244.5(authors)-241.1(declare)-243.6(that)-243.8(they)-243.3(do)-242.3(not)-240(have)-242.8(any)-245.3(compet-)]TJ
0 -1.1847 TD
[(ing)-303.3(interests.)]TJ
/F4 1 Tf
10.4607 0 0 10.4607 313.0582 363.118 Tm
[(Authors)-303.8(Contributions)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 350.192 Tm
[(M.W.)-214.8(wrote)-213.8(the)-215(rst)-213.4(draft)-217.4(of)-212.6(the)-215(article.)-213.3(P.D.C.)-213.2(and)-214.3(B.B.)]TJ
T*
[(provided)-301.2(some)-298(text)-301.9(and)-302.3(modications)5.9(.)]TJ
/F4 1 Tf
10.4607 0 0 10.4607 313.0582 309.8267 Tm
[(Funding)-301.1(Information)]TJ
/F6 1 Tf
10.959 0 0 10.959 313.0582 296.9007 Tm
[(No)-302.6(funding)-298.9(was)-301.6(received)-298.4(for)-298.7(this)-301.9(article.)]TJ
/F4 1 Tf
10.4607 0 0 10.4607 313.0582 270.4818 Tm
(References)Tj
/F7 1 Tf
7.4718 0 0 7.4718 316.7999 260.5038 Tm
[(1.)-507(Scherma)-308.4(M,)-298.5(Masia)-302(P,)-303.9(Deidda)-305.1(M,)-298.5(et)-308.6(al.)-301.4(New)-300.2(perspectives)-310.9(on)-303.1(the)-302.9(use)-301.6(of)]TJ
1.214 -1.1988 TD
[(cannabis)-303.7(in)-304(the)-302.9(treatment)-309.6(of)-298.6(psychiatric)-313.1(disorders.)-307.6(Medic)-9.5(ines)-296.8(\(Basel)-10.7(\).)]TJ
T*
[(2018;5:pii:)-308.2(E107.)]TJ
-1.214 -1.1988 TD
[(2.)-507(American)-305.9(Psychologica)-14.2(l)-294.5(Ass)-9.7(ociation)-302.1(\(APA\).)-309.5(Diagnostic)-302.4(and)-303.9(Statisti)-12.9(cal)]TJ
1.214 -1.1988 TD
[(Manual)-302.1(of)-306.2(Mental)-302.8(Disorders)-304.4(\(5t)-10(h)-297.8(Edition\).)-308.4(American)-305.9(Psychologica)-14.2(l)-294.5(Asso-)]TJ
0 -1.2064 TD
[(ciation:)-304.7(Washingto)-11.8(n,)-298.1(DC,)-305(2013.)]TJ
-1.214 -1.1988 TD
[(3.)-507(Bl)26.4(es)22.4(si)17(ng)-178.3(EM)23.9(,)-197.6(S)0(t)21.9(e)0(e)21.2(n)0(k)26(a)0(m)22.1(p)-196.8(MM)25.8(,)-197.6(M)0(a)29(n)0(z)22.9(a)0(n)21.8(a)0(r)19.5(e)0(s)-182.4(J)15(,)-197.6(e)0(t)-179.6(a)0(l)25.1(.)-197.6(Ca)26.7(nn)19(ab)24.2(id)17.1(i)16.6(o)0(l)-186.1(a)16.2(s)-196.8(a)-188.7(po)18(te)25.3(nt)24.2(ia)17.5(l)]TJ
1.214 -1.1988 TD
[(tr)21.8(ea)23(tm)24.4(en)20.1(t)-292.6(f)17.8(or)-282.7(a)16.2(n)0(x)16(i)16.5(et)17.7(y)-283.2(d)0(i)17.1(s)15.6(or)20.8(de)22.5(rs)18.9(.)-288.6(N)0(e)25.4(u)0(r)20.8(o)0(t)20.8(h)0(e)20.1(r)0(a)19.5(p)15.7(eu)24.3(ti)19.9(cs)22.5(.)-288.6(2)0(0)18.4(1)0(5)26(;)0(1)16.5(2)16.8(:8)16.5(2)16.8(5)0()16(8)16.8(36)18.4(.)]TJ
-1.214 -1.1988 TD
[(4.)-507(Craske)-223.2(MG,)-222.6(Stein)-214.7(MB,)-220.3(Eley)-218.5(TC,)-221.6(et)-217.5(al.)-218(Anxi)-8.4(ety)-219.9(disorders.)-224.1(Nat)-219.9(Rev)-220(Dis)-214.8(Primers.)]TJ
1.214 -1.1988 TD
(2017;3:17024.)Tj
-1.214 -1.1988 TD
[(5.)-507(Murrough)-265.8(JW,)-257.7(Yaqubi)-260.1(S,)-262.5(Sayed)-256.3(S,)-262.5(et)-255.4(al.)-255.9(Emer)-10.9(ging)-254.7(drugs)-260.9(for)-264.9(the)-257.3(treatment)]TJ
1.214 -1.2064 TD
[(of)-298.6(anxiet)-9.5(y.)-298.6(Expert)-306.2(Opin)-307(Emerg)-301.1(Drugs.)-303.8(2015;20)-13.3(:393406.)]TJ
-1.214 -1.1988 TD
[(6.)-507(Bandelow)-305.8(B,)-301.5(Sher)-307.1(L,)-298.6(Bunevicius)-311.1(R,)-303.9(et)-301(al.)-301.4(Guidelines)-307.2(for)-302.8(the)-302.9(pharmaco-)]TJ
1.214 -1.1988 TD
[(logical)-207.7(treatment)-211(of)-207.5(anxiety)-209.2(disorders,)-216.5(obsessive-compu)-16.7(lsive)-201.5(disorder)-216.7(and)]TJ
T*
[(posttraumatic)-314.1(stress)-303.9(disorder)-307.8(in)-304(primary)-305.7(care.)-308.6(Int)-300.7(J)-296.1(Psy)-9.7(chiatry)-299.5(Cli)-9.5(n)-297.8(Pract.)]TJ
T*
(2012;16:7784.)Tj
-1.214 -1.1988 TD
[(7.)-507(Singewald)-307.5(N,)-300.3(Schmuckerma)-15(ir)-298.8(C,)-300.9(Whittle)-303.7(N,)-307.9(et)-301(al.)-301.4(Pharmacology)-308.6(of)-306.1(cog-)]TJ
1.214 -1.2064 TD
[(nitive)-238.5(enhancer)-11.3(s)-234.8(for)-242.1(expo)-10.4(sure-based)-245(therapy)-247.4(of)-237.9(fear,)-244.5(anxiety)-239.5(and)-243.2(trauma-)]TJ
0 -1.1988 TD
[(related)-303.2(disorders.)-315.2(Pharmacol)-306.6(Ther.)-299.8(2015;14)-13.3(9:150190.)]TJ
-1.214 -1.1988 TD
[(8.)-507(Lee)-299.9(JLC,)-303.5(Bertogli)-11.6(o)-301.2(LJ,)-298.8(Guimaraes)-311.7(FS,)-299.4(et)-301(al.)-309(Cannabidiol)-302.7(regula)-9.9(tion)-298.4(of)]TJ
1.214 -1.1988 TD
[(emotion)-306.2(and)-303.9(emotional)-303.9(memory)-304.4(processing:)-315.9(relevance)-301.8(for)-302.8(treati)-11.3(ng)]TJ
T*
[(anxiety-related)-248.3(and)-243.2(substance)-253.4(abuse)-239.4(disorders.)-254.5(Br)-237.2(J)-243(Pharmacol.)-246.2(2017;17)-13.3(4:)]TJ
T*
(32423256.)Tj
/F4 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(194)Tj
42.4515 0 TD
[(WRIGH)-11.1(T)-301.2(E)0(T)-299.4(AL.)]TJ
ET
endstream
endobj
46 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
7.4718 0 0 7.4718 63.496 700.2707 Tm
0 0 0 rg
0 Tc
0 Tw
[(9.)-507(Billakota)-307.2(S,)-300.4(Devinsky)-304.8(O,)-307.3(Marsh)-303(E.)-300.4(Cannabino)-11.9(id)-301.6(therapy)-300.5(in)-304(epilepsy.)-303.6(Curr)]TJ
1.214 -1.2064 TD
[(Opin)-299.4(Neurol)-10.9(.)-296.2(2019;32:220)-16.3(226.)]TJ
-1.7148 -1.1988 TD
[(10.)-505.4(Elliott)-264.4(J,)-258.5(DeJean)-264.8(D,)-254.8(Clifford)-263.7(T,)-262.5(et)-255.4(al.)-263.5(Cannabis-based)-262.1(products)-268.8(for)-264.9(pediatric)]TJ
1.7224 -1.1988 TD
[(epilepsy:)-311.2(a)-294.9(systematic)-314.4(review.)-306.7(Epilepsia.)-302.3(2019;60)-13.3(:619.)]TJ
-1.7224 -1.1988 TD
[(11.)-505.4(Lattanzi)-311(S,)-300.4(Brigo)-303.8(F,)-302.8(Trinka)-306.4(E,)-300.4(et)-301(al.)-301.4(Efcacy)-311.4(and)-296.3(safety)-306.9(of)-306.1(cannabidiol)-306.2(in)]TJ
1.7224 -1.1988 TD
[(epilepsy:)-311.2(a)-294.9(systematic)-314.4(review)-306.4(and)-296.3(meta-analys)-15.4(is.)-302(Drugs.)-303.8(2018;78:1791)-14.7()]TJ
T*
(1804.)Tj
-1.7224 -1.2064 TD
[(12.)-505.4(Stockings)-307.2(E,)-308(Zagic)-298.1(D,)-307.9(Campbell)-305.9(G,)-303.7(et)-301(al.)-301.4(Evidence)-301.4(for)-302.8(can)-9.2(nabis)-302.1(and)-303.9(can-)]TJ
1.7224 -1.1988 TD
[(nabinoids)-307.5(for)-302.8(epilepsy:)-311.2(a)-294.9(s)0(y)-9.6(stematic)-304.8(review)-306.4(of)-298.6(controlle)-12.2(d)-295.4(and)-303.9(observa-)]TJ
T*
[(tional)-303.7(evidence)-9.7(.)-296.2(J)-303.7(Neurol)-306.8(Neurosurg)-311.6(Psychiatry.)-309.6(2018;89:741753.)]TJ
-1.7224 -1.1988 TD
[(13.)-505.4(Zaheer)-304.6(S,)-300.4(Kumar)-311.5(D,)-300.3(Khan)-304.1(MT,)-302.7(et)-301(al.)-301.4(Epilepsy)-306.7(and)-303.9(cannabis:)-304(a)-302.5(literature)]TJ
1.7224 -1.1988 TD
[(review.)-306.7(Cureus.)-308.5(2018;10:e3278.)]TJ
-1.7224 -1.1988 TD
[(14.)-505.4(Zuardi)-304.6(AW,)-306(Cosme)-307.9(RA,)-299.4(Graeff)-309.8(FG,)-302.8(et)-301(al.)-301.4(Effects)-307.7(of)-298.6(ipsapi)-10(rone)-300.6(and)-303.9(canna-)]TJ
1.7224 -1.1988 TD
[(bidiol)-303.7(on)-303.1(human)-305.7(experimental)-311(anxiety.)-300.5(J)-303.7(Psychophar)-14.7(macol.)-301.5(1993;7\(1)]TJ
0 -1.2064 TD
[(Suppl.\):8)-13.4(288.)]TJ
-1.7224 -1.1988 TD
[(15.)-505.4(Bergamas)-11.6(chi)-244(MM,)-247.7(Queiroz)-250.9(RH,)-250.8(Chagas)-248.9(MH,)-245.3(et)-247.9(al.)-248.3(Cannabidiol)-257.1(reduces)-253.7(the)]TJ
1.7224 -1.1988 TD
[(anxiety)-307.8(induced)-302.2(by)-305.4(simulated)-310.9(public)-305.7(speaking)-299.7(in)-304(treatment-nai)-14.8(ve)-295.7(social)]TJ
T*
[(phobia)-307.4(patients.)-304.2(Neurop)-11.7(sychopharmacology.)-318.2(2011;36:12191226)-16.6(.)]TJ
-1.7224 -1.1988 TD
[(16.)-505.4(McGuire)-224.4(P,)-220.5(Robson)-224.2(P,)-212.9(Cubala)-226.2(WJ,)-219.8(et)-217.5(al.)-218(Cannabidiol)-226.8(\(CBD\))-218.5(as)-218.6(an)-213.4(adj)-9.9(unctive)]TJ
1.7224 -1.1988 TD
[(therapy)-247.4(in)-235.7(sch)-9.7(izophrenia:)-243.4(a)-241.8(multicenter)-248.8(randomized)-243.7(controlle)-12.2(d)-234.7(trial.)-247.9(Am)-239.9(J)]TJ
0 -1.2064 TD
[(Psychiatry.)-309.6(2018;17)-13.3(5:225231.)]TJ
-1.7224 -1.1988 TD
[(17.)-505.4(Leweke)-302.6(FM,)-305.1(Piomelli)-305.9(D,)-300.3(Pahlisch)-311.6(F,)-295.2(et)-308.6(al.)-301.4(Cannabidiol)-302.7(enhances)-310.1(ananda-)]TJ
1.7224 -1.1988 TD
[(mide)-304.1(signaling)-305.6(and)-303.9(alleviates)-301.9(psych)-11.7(otic)-304.8(symptoms)-309.9(of)-298.6(schizophren)-12.4(ia.)]TJ
T*
[(Translational)-310.3(Psychiatry.)-309.6(2012;2:e9)-14.4(4.)]TJ
-1.7224 -1.1988 TD
[(18.)-505.4(Crippa)-309.1(JAS,)-303.6(Hallak)-301.2(JEC,)-305.3(Zuardi)-304.6(AW,)-306(et)-301(al.)-301.4(Is)-301.7(cannab)-9.6(idiol)-296.6(the)-302.9(ideal)-307.7(drug)-299.3(to)]TJ
1.7224 -1.1988 TD
[(treat)-285.8(non-motor)-289.4(Parkinsons)-286.2(disease)-286.2(symptoms?)-286.7(Eur)-286.9(Arch)-283(Psychiatry)-286.5(Clin)]TJ
0 -1.2064 TD
[(Neurosc)-12.5(i.)-294.8(2019;26)-13.3(9:121133.)]TJ
-1.7224 -1.1988 TD
[(19.)-505.4(Couch)-306.2(DG,)-307.9(Maudslay)-301.7(H,)-303.7(Dolema)-9.6(n)-297.8(B)0(,)-301.5(e)0(t)-301(al.)-301.4(The)-302.8(use)-301.6(of)-306.1(cannabinoids)-309.1(in)]TJ
1.7224 -1.1988 TD
[(colitis:)-309.5(a)-302.5(systematic)-306.8(review)-306.4(and)-303.9(meta-analysis.)-309.8(Inamm)-302.3(Bowel)-305.4(Dis.)-306.1(2018;)]TJ
T*
[(24:68069)-12.5(7.)]TJ
-1.7224 -1.1988 TD
[(20.)-505.4(Turna)-265.1(J,)-266.1(Syan)-265.5(SK,)-260.2(Frey)-264.5(BN,)-267.7(et)-263(al.)-255.9(Cannabi)-12.3(diol)-260(as)-264.1(a)-257(novel)-263.6(can)-9.2(didate)-259.7(alcoho)-10.9(l)]TJ
1.7224 -1.1988 TD
[(use)-233.3(disorder)-231.9(pharmac)-13.6(otherapy:)-230.3(a)-234.2(systematic)-238.5(review.)-230.8(Alcohol)-233.5(Clin)-231.5(Exp)-236.2(Res.)]TJ
T*
[(2019;43:5505)-15.5(63.)]TJ
-1.7224 -1.2064 TD
[(21.)-505.4(Urits)-310.2(I,)-294.8(Borchar)-13.2(t)-300.2(M)0(,)-298.5(Hasegawa)-309.8(M,)-298.5(et)-301(al.)-309(An)-300.8(update)-304.3(of)-298.6(current)-309.8(cannabis-)]TJ
1.7224 -1.1988 TD
[(based)-301.9(ph)-9(armaceuticals)-307.5(in)-304(pain)-302.5(medicine.)-306.4(Pain)-303.2(Ther.)-299.8(2019;8:4)-13.6(151.)]TJ
-1.7224 -1.1988 TD
[(22.)-505.4(Noreen)-305.5(N,)-300.3(Muham)-10.2(mad)-296.1(F,)-302.8(Akhta)-10.7(r)-300.2(B)0(,)-301.5(e)0(t)-301(al.)-301.4(Is)-301.7(cannabidio)-11.7(l)-294.5(a)-302.5(promising)]TJ
1.7224 -1.1988 TD
[(substance)-306.5(for)-310.4(new)-298(drug)-306.9(development?)-307.6(A)-298.9(review)-306.4(of)-306.1(its)-298.4(potential)-308.3(thera-)]TJ
T*
[(peutic)-305.1(application)-12.7(s.)-303.3(Crit)-300.2(Rev)-303.5(Eukaryot)-308(Gene)-306.9(Expr.)-301.4(2018;28:7386)-15.5(.)]TJ
-1.7224 -1.1988 TD
[(23.)-505.4(Morales)-305.8(P,)-303.9(Hurst)-309.3(DP,)-300.5(Reggio)-304.6(PH.)-303.9(Molecular)-303.3(targe)-10.3(ts)-299.7(of)-298.6(the)-302.9(phytoca)-13.1(nnabi-)]TJ
1.7224 -1.2064 TD
[(noids:)-308.7(a)-294.9(complex)-307.3(pict)-10.7(ure.)-299(Prog)-307.5(Chem)-304.9(Org)-298(Nat)-303.3(Prod.)-305.4(2017;103)-11.7(:103131.)]TJ
-1.7224 -1.1988 TD
[(24.)-505.4(Ibeas)-308.6(Bih)-301.8(C,)-300.9(Chen)-305.2(T,)-300.4(Nunn)-301.6(AV,)-301.1(et)-301(al.)-301.4(Molecul)-11.7(ar)-299.2(targets)-310(of)-298.6(cannab)-9.6(idiol)-296.6(in)]TJ
1.7224 -1.1988 TD
[(neurologica)-14.2(l)-294.5(disorders.)-315.2(Neurotherapeutic)-16.5(s.)-295.8(2015;12)-13.3(:699730.)]TJ
-1.7224 -1.1988 TD
[(25.)-505.4(Papagianni)-310.8(EP,)-300.5(Stevenson)-306.1(CW.)-307.7(Cannabinoid)-305.9(regulation)-308.4(of)-306.1(fear)-297.3(and)-303.9(anxi-)]TJ
1.7224 -1.1988 TD
[(ety:)-303.7(an)-304.4(update.)-304.6(Curr)-306.9(Psychiatry)-309.3(Rep.)-304.2(2019;21:38.)]TJ
-1.7224 -1.1988 TD
.0115 Tc
[(26.)-497.1(Camp)11.5(o)-8.5(s)-299.1(AC,)-299.9(G)-3.6(u)11.5(i)-7.6(mara)11.5(e)-3.5(s)-299.1(FS.)-299.9(I)11.5(n)-11.8(v)11.5(o)-8(l)11.5(v)-8.9(e)3.1(me)-4.5(nt)-296.3(of)-296.9(5H)-3.6(T1)11.5(A)-308.6(r)-.4(ec)11.5(e)-12.7(p)11.5(t)-7.4(o)-1.4(rs)-299.1(i)11.5(n)-307.7(the)]TJ
1.7527 -1.1988 TD
0 Tc
[(a)-14.2(n)-9.5(x)-12.4(i)0(o)-19.1(l)0(y)-23.8(t)0(i)-18.1(c)0(-)-24.9(l)0(i)-20(k)-10(e)-311.9(e)-8.4(f)-12.5(f)-12.5(e)-8.4(ct)-20.1(s)-310.6(o)-12.9(f)-308.4(c)-15.8(an)-16.1(n)-17.1(a)0(b)-21.3(i)0(d)-20.9(i)0(o)-19.1(l)-309.7(i)-13.8(n)-9.5(j)-11.4(e)-8.4(ct)-20.1(e)-16(d)-310.6(in)-15.7(t)-11.9(o)-316.4(t)-11.9(h)-9.5(e)-304.3(d)-14.7(o)-12.9(r)-11.9(so)-20(l)-13.8(a)0(t)-18.5(e)-8.4(r)-11.9(a)-14.2(l)]TJ
0 -1.2064 TD
[(p)-14.7(e)-8.4(r)-11.9(i)0(a)-20.4(q)0(u)-20(e)-8.4(d)-14.7(u)-12.9(ct)-20.1(a)-14.2(l)-279.4(g)-9.5(r)-11.9(a)-14.2(y)-283.2(o)-12.9(f)-285.7(r)-11.9(a)0(t)-18.5(s)-14.7(.)-281(P)-15.3(sy)-17.2(c)-15.8(h)-9.5(o)-12.9(p)0(h)-16.6(a)-14.2(r)-11.9(m)-9.2(a)-14.2(c)0(o)-21.2(l)0(o)-19.1(g)-9.5(y)-290.8(\()0(B)-20.2(e)-8.4(r)-11.9(l)-13.8(\).)-295.9(20)-19.5(0)-13.5(8)0(;)-21.4(1)0(9)-19.5(9)-13.5(:2)-21.4(23)-19.5()]TJ
0 -1.1988 TD
.0135 Tc
[(23)13.5(0)-6(.)]TJ
-1.7527 -1.1988 TD
0 Tc
[(27.)-505.4(De)-270.5(Petrocellis)-269.7(L,)-268.3(Li)-8.7(gresti)-267.4(A,)-268.9(Moriello)-271.9(AS,)-265.5(et)-270.6(al.)-271.1(Effects)-269.7(of)-268.2(cannabin)-10.2(oids)-268.6(and)]TJ
1.7224 -1.1988 TD
[(cannab)-9.6(inoid-enriched)-309.9(Cannabis)-307.7(extracts)-306.1(on)-303.1(TRP)-300.4(channels)-307.9(and)-303.9(endocan-)]TJ
T*
[(nabinoid)-307.9(metabolic)-304.4(enz)-8.2(ymes.)-300.6(Br)-305.5(J)-296.1(Pha)-8.7(rmacol.)-305.8(2011;163:1479149)-16.6(4.)]TJ
-1.7224 -1.1988 TD
[(28.)-505.4(Crippa)-309.1(JA,)-299.4(Derenu)-9.6(sson)-302.3(GN,)-300.3(Ferrari)-306.2(TB,)-305.7(et)-301(al.)-301.4(Neural)-308.1(basis)-299.8(of)-306.2(anxiolytic)-310.3(ef-)]TJ
1.7224 -1.2064 TD
[(fects)-306.1(of)-306.1(cannabidiol)-306.3(\(CBD\))-301.9(in)-304(generalized)-307.7(social)-305.3(anxiety)-300.2(diso)-10.6(rder:)-305(a)-294.9(pre-)]TJ
0 -1.1988 TD
[(liminary)-308.7(report.)-307(J)-303.7(Psychopharmacol.)-316.3(2011;25:121130.)]TJ
-1.7224 -1.1988 TD
[(29.)-505.4(Bisogno)-306.3(T,)-300.4(Hanus)]TJ
8.6422 .0304 TD
()Tj
.6449 -.0304 TD
[(L,)-298.6(De)-300.8(Pe)-8.5(trocellis)-306.7(L,)-298.6(et)-301(al.)-301.4(Molecul)-11.7(ar)-299.2(targets)-310(for)-302.8(canna-)]TJ
-7.5648 -1.1988 TD
[(bidiol)-303.7(and)-303.9(its)-306(synthetic)-302.8(analogu)-11.1(es:)-296.5(effect)-312.3(on)-295.5(vanilloid)-310.4(VR1)-303.9(receptors)-307.8(and)]TJ
T*
[(on)-303.1(the)-302.9(cellular)-301.9(uptake)-307.2(and)-303.9(enzymatic)-310.8(hydrolysis)-308.2(of)-298.6(anan)-9.4(damide.)-302.9(Br)-305.5(J)]TJ
T*
[(Pharmaco)-12(l.)-294.8(2001;13)-13.3(4:845852.)]TJ
-1.7224 -1.1988 TD
[(30.)-505.4(Patel)-306.4(S,)-300.4(Hillard)-302.1(CJ.)-308.7(Pharmacological)-310.8(evaluation)-307.9(of)-306.1(cannabinoid)-301.9(receptor)]TJ
1.7224 -1.2064 TD
[(ligands)-302.7(in)-304(a)-302.5(mouse)-301(model)-309.4(of)-298.6(anxiet)-9.5(y:)-298.6(further)-306.5(evidence)-305.6(for)-302.8(an)-304.4(anxiolytic)]TJ
0 -1.1988 TD
[(role)-282.2(for)-287.7(endogenous)-287.9(cannabinoid)-286.8(signaling.)-283.1(J)-280.9(Pharmacol)-291.4(Exp)-281.7(Ther.)-277(2006;)]TJ
T*
[(318:3043)-12.5(11.)]TJ
-1.7224 -1.1988 TD
[(31.)-505.4(Hasin)-264.6(DS,)-259(Sarvet)-262(AL,)-263.7(Cerda)]TJ
12.3298 .0303 TD
()Tj
.6449 -.0303 TD
[(M,)-260.6(et)-255.4(al.)-263.5(US)-262.1(adult)-257.1(illic)-10.4(it)-253.3(can)-9.2(nabis)-256.6(use,)-263.9(cannabis)]TJ
-11.2523 -1.1988 TD
[(use)-301.6(disorder,)-308(an)-8.5(d)-295.4(medical)-310(marijuana)-308.6(laws:)-300.4(19911992)-306.5(to)-305.5(20122013.)]TJ
T*
[(JAMA)-304.5(Psychiatry.)-309.6(2017;74:579)-16.3(588.)]TJ
-1.7224 -1.2064 TD
[(32.)-505.4(Martins)-305.9(SS,)-304.6(Mauro)-304.6(CM,)-303.2(Santaella-T)-11.2(enorio)-304.6(J,)-304(et)-301(al.)-301.4(State-level)-307.9(medical)]TJ
1.7224 -1.1988 TD
[(marijuana)-308.6(laws,)-308(marijuana)-301(use)-309.2(and)-296.3(perceiv)-11.3(ed)-296.2(availabili)-11.5(ty)-302.6(of)-298.6(marijuana)]TJ
T*
[(among)-305.7(the)-302.9(general)-303.2(U.S.)-308.2(population.)-306(Drug)-303.9(Alcohol)-309.4(Depend.)-302.8(2016;169)-11.7(:)]TJ
T*
(2632.)Tj
-1.7224 -1.1988 TD
[(33.)-505.4(Wen)-305.4(H,)-303.7(Hockenberry)-310.7(JM,)-298.7(Cummi)-11.9(ngs)-299.3(JR.)-304.1(The)-302.8(effect)-304.7(of)-298.6(medical)-310(marijuana)]TJ
1.7224 -1.1988 TD
[(laws)-307.7(on)-295.5(adoles)-10.4(cent)-303.6(and)-303.9(adult)-302.7(use)-301.6(of)-298.6(ma)-8.3(rijuana,)-300.6(alcoho)-10.9(l,)-302.4(and)-296.3(other)-304.9(sub-)]TJ
T*
[(stances.)-309.6(J)-303.7(Health)-300.5(Econ.)-308.3(2015;42:6480.)]TJ
31.8829 85.2005 TD
[(34.)-505.4(Ifand)-303.4(K,)-301.5(Grotenhermen)-308.6(F.)-302.8(An)-300.8(update)-304.3(on)-303.1(safety)-306.9(and)-303.9(side)-302(effects)-304.3(of)-306.1(can-)]TJ
1.7224 -1.2064 TD
[(nabidiol:)-304.9(a)-302.5(review)-298.8(of)-306.1(clinical)-300.3(data)-305.3(and)-303.9(relevant)-304.6(animal)-302.4(studies.)-311.4(Cannabis)]TJ
0 -1.1988 TD
[(Cannabinoid)-305.9(Res.)-304.3(2017;2:139154.)]TJ
-1.7224 -1.1988 TD
[(35.)-505.4(World)-302.9(Health)-300.5(Org)-9.7(anization)-302.5(\(WHO\).)-306(Cannabid)-11.7(iol)-298.5(\(CBD\))-301.9(Critical)-312.3(Review)]TJ
1.7224 -1.1988 TD
[(Report.)-302.9(Geneva,)-305.3(Switzerland:)-312.4(WHO,)-306.5(2018.)]TJ
-1.7224 -1.1988 TD
[(36.)-505.4(Fasinu)-299.4(PS,)-308.1(Phillips)-299.1(S,)-308(ElSohly)-303.7(MA,)-301.5(et)-301(al.)-301.4(Curre)-11.7(nt)-302.1(status)-300.3(and)-303.9(prospect)-13.9(s)-295.5(for)]TJ
1.7224 -1.1988 TD
[(cannabidiol)-306.3(preparations)-312(as)-302.1(new)-298(therape)-10.6(utic)-304.8(agents.)-303.7(Pharmacothera)-14.7(py.)]TJ
0 -1.2064 TD
(2016;36:781796.)Tj
-1.7224 -1.1988 TD
[(37.)-505.4(Bergamaschi)-255.6(MM,)-255.3(Queiroz)-258.5(RH,)-250.8(Zuar)-10.5(di)-248.5(AW,)-252.9(et)-255.4(al.)-255.9(Safety)-250.9(and)-258.4(side)-256.4(effects)-251.2(of)]TJ
1.7224 -1.1988 TD
[(cannabidiol,)-207.9(a)]TJ
/F11 1 Tf
5.9562 0 TD
[(Cannabis)-212.4(sativa)]TJ
/F7 1 Tf
6.5556 0 TD
[(const)-11.7(ituent.)-205.2(Curr)-208.2(Drug)-212.9(Saf.)-205.7(2011;6:2)-13.6(37249.)]TJ
-14.2342 -1.1988 TD
[(38.)-505.4(World)-295.3(Health)-300.5(Organization)-304.6(\(WHO\).)-306(Fortieth)-299.2(Report.)-302.9(Geneva,)-297.7(Switzerland:)]TJ
1.7224 -1.1988 TD
[(WHO,)-298.9(2018.)]TJ
-1.7224 -1.1988 TD
[(39.)-505.4(Hindocha)-302.8(C,)-300.9(Freeman)-311(TP,)-300.5(Schafer)-304.1(G,)-303.7(et)-301(al.)-301.4(Acute)-310(effects)-304.3(of)-306.2(delta-9-)]TJ
1.7224 -1.1988 TD
[(tetrahydrocannabinol)-17.4(,)-296.2(cannab)-9.6(idiol)-304.2(and)-296.3(their)-305.8(combination)-312.7(on)-303.1(facial)]TJ
0 -1.2064 TD
[(emotion)-306.2(recognition:)-304.7(a)-302.5(randomised,)-313.9(double-blind,)-304.9(placebo)-11(-controlled)]TJ
0 -1.1988 TD
[(study)-299.4(in)-304(cannabis)-303.7(users.)-313.3(Eur)-302.1(Neuropsychopharmac)-20.1(ol.)-300.1(2015;25:325334.)]TJ
-1.7224 -1.1988 TD
[(40.)-505.4(Babalonis)-302.8(S,)-300.4(Hane)-9.3(y)-298.3(M)0(,)-298.5(Malcol)-12.2(m)-297.5(RJ,)-304.1(et)-301(al.)-301.4(Oral)-301.3(cannab)-9.6(idiol)-304.2(does)-301.1(not)-299.8(pro-)]TJ
1.7224 -1.1988 TD
[(duce)-302.2(a)-302.5(signal)-303.2(for)-302.8(abuse)-300.1(liabilit)-11.1(y)-298.3(i)0(n)-304(frequent)-302.5(marijuana)-308.6(smokers.)-309.8(Drug)]TJ
T*
[(Alcohol)-301.8(Depend.)-310.4(2017;172:913.)]TJ
-1.7224 -1.1988 TD
[(41.)-505.4(Schoedel)-300.1(KA,)-304.5(Szeto)-308.4(I,)-302.4(Setnik)-300.6(B,)-301.5(et)-301(al.)-309(Abuse)-304.1(potential)-300.7(assess)-13.2(ment)-297(of)-306.2(can-)]TJ
1.7224 -1.2064 TD
[(nabidiol)-304.6(\(CBD\))-301.9(in)-304(recreational)-306(polydrug)-312.8(users:)-305.7(a)-294.9(rando)-10(mized,)-302.3(double-)]TJ
0 -1.1988 TD
[(blind,)-301.9(controlled)-307.6(trial.)-308.6(Epilepsy)-306.7(Behav.)-302.3(2018;88:1621)-15.5(71.)]TJ
-1.7224 -1.1988 TD
[(42.)-505.4(Haney)-300(M,)-306.1(Malcolm)-302.1(RJ,)-304.1(Babalonis)-310.4(S,)-300.4(et)-301(al.)-301.4(Oral)-301.3(cannab)-9.6(idiol)-304.2(does)-301.1(not)-299.8(alter)]TJ
1.7224 -1.1988 TD
[(the)-287.7(subjective,)-301(reinforcing)-296.4(or)-290.3(cardiova)-13.1(scular)-295.8(effects)-296.7(of)-291(smoked)-290(canna)-10.1(bis.)]TJ
T*
[(Neuropsychopharmacolo)-21.8(gy.)-300.5(2016;41:19741982)-16.6(.)]TJ
-1.7224 -1.1988 TD
[(43.)-505.4(Solowij)-243(N,)-247.2(Broyd)-252(S,)-247.3(Greenwood)-252.5(LM,)-247.8(et)-247.9(al.)-240.7(A)-245.8(rando)-10(mised)-242.9(control)-12.8(led)-241.7(trial)-247.6(of)]TJ
1.7224 -1.2064 TD
[(vaporised)-301.5(delta)-9.8(\(9\)-tetrahydrocannabi)-18.5(nol)-301.8(and)-296.3(can)-9.2(nabidiol)-304.6(alone)-301.6(and)-303.9(in)]TJ
0 -1.1988 TD
[(combination)-305.2(in)-304(frequent)-302.5(and)-303.9(infreq)-10(uent)-300.6(cannabis)-303.7(users:)-305.7(acute)-306(intoxica-)]TJ
T*
[(tion)-298.4(effects.)-312.1(Eur)-302.1(Arch)-305.8(Psychiatry)-309.3(Clin)-299.7(Neurosc)-12.5(i.)-294.8(2019;26)-13.3(9:1735.)]TJ
-1.7224 -1.1988 TD
[(44.)-505.4(Guimara)]TJ
4.8712 .0076 TD
()Tj
.3794 -.0076 TD
[(es)-303.8(FS,)-307(Chiaretti)-304.8(TM,)-302.7(Graeff)-309.8(FG,)-302.8(et)-301(al.)-301.4(Antianxiety)-308.1(effect)-304.7(of)-298.6(can)-9.2(na-)]TJ
-3.5282 -1.1988 TD
[(bidiol)-303.7(in)-296.4(the)-302.9(elevated)-306.3(plus-maz)-10.7(e.)-297(Psychophar)-14.7(macology)-303.3(\(Berl\).)-304.7(1990;100)-11.7(:)]TJ
T*
(558559.)Tj
-1.7224 -1.1988 TD
[(45.)-505.4(Onaivi)-296.6(ES,)-304.6(Green)-303.6(MR,)-306.2(Martin)-306.3(BR.)-301.7(Pharmacologica)-16.2(l)-294.5(character)-14.9(ization)-301.6(of)]TJ
1.7224 -1.2064 TD
[(cannabinoids)-248.4(in)-250.9(the)-242.2(ele)-7.8(vated)-245.4(plus)-253.4(maze.)-242.5(J)-250.6(Pharmacol)-253.5(Exp)-243.8(Ther.)-254.3(1990;253:)]TJ
0 -1.1988 TD
(10021009.)Tj
-1.7224 -1.1988 TD
[(46.)-505.4(Zuardi)-304.6(AW,)-298.5(Shirak)-10.5(awa)-301(I,)-302.4(Finkelfarb)-305.1(E,)-300.4(et)-301(al.)-301.4(Actio)-11.9(n)-297.8(o)0(f)-298.6(can)-9.2(nabidiol)-304.6(on)-303.1(the)]TJ
1.7224 -1.1988 TD
[(anxiety)-300.2(and)-303.9(other)-304.9(effects)-304.3(produced)-310.8(by)-305.4(delta)-298.1(9-THC)-312.2(in)-296.4(normal)-306.7(subjects.)]TJ
T*
[(Psychopharmacology)-318.1(\(Berl\).)-304.7(1982;76:245250.)]TJ
-1.7224 -1.1988 TD
[(47.)-505.4(Karniol)-301.4(IG,)-302.4(Shirak)-10.5(awa)-301(I,)-302.4(Kasinski)-301(N,)-307.9(et)-301(al.)-301.4(Cannabidiol)-310.2(interferes)-308.5(with)-300.1(the)]TJ
1.7224 -1.2064 TD
[(effects)-236(of)-237.9(delta)-237.4(9-tetrahydrocannab)-20.4(inol)-232.1(in)-235.7(man.)-238.1(Eur)-233.8(J)-235.4(Pha)-8.7(rmacol.)-237.5(1974;28:)]TJ
0 -1.1988 TD
(172177.)Tj
7.4718 0 0 7.4718 310.8472 332.6172 Tm
.0141 Tc
[(48.)-502.1(C)-5.7(r)-5.3(ippa)-303.6(JA,)-297.3(Z)-3(u)-6.4(a)-.1(rdi)-303.2(A)-4.1(W,)-304.9(Gar)-5.3(r)2.2(i)-7.3(d)-.6(o)-302.3(G)-1(E,)-304.9(et)-301.3(al)-7.3(.)-297.3(E)-5.3(ff)-6(ects)-304.1(of)-301.9(ca)-7.7(nnab)-8.1(idio)-6.4(l)-295.6(\()-.8(C)-5.7(B)1.2(D)-5.2(\))]TJ
1.7603 -1.1988 TD
.0147 Tc
[(o)-5.8(n)-298.3(r)-4.7(e)-1.3(gional)-302.6(cer)-4.7(e)6.3(b)-7.5(r)2.8(al)-302.6(bl)-6.7(ood)-303.5()-4(o)1.8(w.)-304.3(N)-4.6(e)-1.2(ur)-4.7(opsycho)-5.8(p)0(harmaco)-5.8(l).9(o)-5.8(g)5.2(y.)-304.3(200)-6.4(4;29)-6.4(:)]TJ
T*
.0139 Tc
[(4)-7.2(174)-7.2(26.)]TJ
-1.7603 -1.1988 TD
0 Tc
[(49.)-505.4(Fusar-Poli)-277(P,)-281.2(Crippa)-278.7(JA,)-284.3(Bhattacharyya)-289.2(S,)-277.6(et)-278.2(al.)-271.1(Dis)-9.9(tinct)-275.3(effects)-281.5(of)-283.4({delta}9-)]TJ
1.7224 -1.1988 TD
[(tetrahydrocannabinol)-305.8(and)-288.7(can)-9.2(nabidiol)-289.5(on)-295.5(neural)-298.3(activation)-299.1(during)-292.3(emo-)]TJ
0 -1.2064 TD
[(tional)-303.7(processing.)-308.3(Arch)-305.8(Gen)-298.6(Psyc)-10.4(hiatry.)-299.2(200)-10.3(9;66:95105.)]TJ
-1.7224 -1.1988 TD
[(50.)-505.4(Linares)-264.6(IM,)-259.2(Zuardi)-259(AW,)-268.1(Pereira)-258.3(LC,)-265.4(et)-263(al.)-255.9(Cannabi)-12.2(diol)-260.1(presents)-268.6(an)-258.9(inverted)]TJ
1.7224 -1.1988 TD
[(U-shaped)-236.9(dose-response)-246(curve)-245.3(in)-228.2(a)-241.8(simulated)-242.6(public)-237.5(speaking)-239(test.)-244.4(Braz)-234.1(J)]TJ
T*
[(Psychiatry.)-309.6(2019;41:914.)]TJ
-1.7224 -1.1988 TD
[(51.)-505.4(Borgwardt)-304(SJ,)-308.2(Allen)-298.9(P,)-303.9(Bhattacharyya)-311.9(S,)-300.4(et)-301(al.)-301.4(Neural)-308.1(basis)-307.4(of)-298.6(Delta-9-)]TJ
1.7224 -1.1988 TD
[(tetrahydrocannabinol)-313.4(and)-303.9(cannabidiol:)-306.5(effects)-311.9(during)-299.8(respon)-11.3(se)-296.3(in)-8.1(hibi-)]TJ
0 -1.2064 TD
[(tion.)-298.7(Biol)-303.8(Psychi)-10.9(atry.)-298.6(2008;64)-13.3(:966973.)]TJ
-1.7224 -1.1988 TD
[(52.)-505.4(Fusar-Poli)-299.8(P,)-296.3(Allen)-298.9(P,)-296.3(Bhat)-10.5(tacharyya)-301.4(S,)-300.4(et)-293.4(al.)-301.4(Modulation)-301(of)-298.6(effective)-303.1(con-)]TJ
1.7224 -1.1988 TD
[(nectivity)-306.6(during)-299.8(emoti)-10.7(onal)-300.8(processing)-308(by)-305.4(Delta)-302.8(9-tetrahydrocannabi)-19.1(nol)]TJ
T*
[(and)-296.3(canna)-10.1(bidiol.)-304(Int)-300.7(J)-303.7(Neuropsychopharmacol.)-320.3(2010;13:421432.)]TJ
-1.7224 -1.1988 TD
[(53.)-505.4(Soares)-301.5(VP,)-305.8(Campos)-305.6(AC.)-303.9(Evidences)-308.6(for)-302.8(the)-302.9(anti-panic)-308.6(actions)-305.3(of)-298.6(cannab)-9.6(i-)]TJ
1.7224 -1.1988 TD
[(diol.)-298.3(Curr)-306.9(Neuropharmaco)-16(l.)-302.4(2017;15:291299.)]TJ
-1.7224 -1.1988 TD
[(54.)-505.4(Elms)-262(L,)-260.7(Shannon)-266.6(S,)-254.9(Hughe)-9.9(s)-257.5(S)0(,)-262.5(e)0(t)-263(al.)-255.9(Cannabid)-11.7(iol)-260.6(in)-258.5(the)-257.3(treatment)-271.7(of)-260.6(post-)]TJ
1.7224 -1.2064 TD
[(traumatic)-290.3(stress)-288.8(disorder:)-285.3(a)-287.3(case)-280.8(series.)-292.2(J)-280.9(Altern)-286(Complement)-292.3(Med.)-283.6(2019;)]TJ
0 -1.1988 TD
(25:392397.)Tj
-1.7224 -1.1988 TD
[(55.)-505.4(Shannon)-236.2(S,)-239.7(Lewis)-243.6(N,)-232(Lee)-239.2(H,)-243(et)-232.7(al.)-240.7(Cannabidiol)-242(in)-243.3(anxiety)-239.5(and)-235.6(sleep:)-242.4(a)-234.2(lar)-9.5(ge)]TJ
1.7224 -1.1988 TD
[(case)-303.5(series.)-299.8(Perm)-310.3(J.)-296.4(2019;23:)-13.6(18041.)]TJ
-1.7224 -1.1988 TD
[(56.)-505.4(Shannon)-281.7(S,)-277.6(Opila-Lehman)-289.2(J.)-281.2(Effectiveness)-285.6(of)-283.4(cannabidiol)-283.5(oil)-283.3(for)-280.1(pediatric)]TJ
1.7224 -1.1988 TD
[(anxiety)-300.2(and)-296.3(insomnia)-295(as)-302.1(part)-295.4(of)-298.6(posttrauma)-14.6(tic)-291.9(stress)-303.9(disorder:)-300.5(a)-302.5(case)-296(re-)]TJ
0 -1.2064 TD
[(port.)-302(Perm)-302.8(J.)-304(2016;20:16-005)-14.6(.)]TJ
-1.7224 -1.1988 TD
[(57.)-505.4(van)-280.7(der)-277.7(Flier)-282.1(FE,)-284.3(Kwee)-279.5(CMB,)-285.7(Cath)-283(DC,)-282.2(et)-278.2(al.)-278.7(Cannabi)-12.3(diol)-282.8(enhancement)-281.2(of)]TJ
1.7224 -1.1988 TD
[(exposure)-301.1(thera)-10.3(py)-297.8(in)-304(treatment)-309.6(refractory)-311(patients)-303.9(with)-300.1(ph)-9(obias:)-305.8(study)]TJ
T*
[(protocol)-304(of)-306.1(a)-294.9(rando)-10(mized)-302(controlled)-307.6(trial.)-308.6(BMC)-300.6(Psychiatry.)-309.6(2019;19:)-13.6(69.)]TJ
-1.7224 -1.1988 TD
[(58.)-505.4(Ameringen)-265.3(MV.)-270.1(Cannabid)-11.7(iol)-268.1(for)-264.9(the)-272.5(treatment)-271.6(of)-268.2(anxiety)-269.9(disorders:)-277.3(an)-266.5(8-)]TJ
1.7224 -1.1988 TD
[(week)-299.4(pilot)-302.3(study.)-307.3(Clinic)-10.7(alTrials.gov.)-304.7(NCT03549)-12.5(819.)-298.9(Publi)-9.8(shed)-297.7(2019.)]TJ
T*
[(Accessed)-308.1(2019.)]TJ
/F4 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(U)-5.9(S)0(E)-298(O)0(F)-308.4(CANNA)-9.3(BIDIOL)-308.8(FOR)-300.2(THE)-306.7(TREAT)-9.9(MENT)-305.8(OF)-302.8(ANXI)-8(ETY)-21973.5(195)]TJ
ET
endstream
endobj
51 0 obj
<>stream
0 0 0 rg
/GS1 gs
1 i
q 1 0 0 1 313.058 411.08 cm 0 0 m
.113 1.02 l
.671 3.657 2.352 5.339 4.989 5.896 c
6.009 5.953 l
6.009 4.989 l
5.159 4.932 l
3.117 4.572 1.438 2.893 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 546.236 417.033 cm 0 0 m
1.02 -.057 l
3.385 -.504 5.556 -2.479 5.839 -4.932 c
5.953 -5.953 l
4.932 -5.953 l
4.876 -5.102 l
4.613 -3.125 2.783 -1.327 .85 -1.02 c
0 -.964 l
f*
Q
319.068 416.069 227.168 .96378 re
f
q 1 0 0 1 319.068 367.257 cm 0 0 m
-1.02 .057 l
-3.697 .624 -5.289 2.289 -5.896 4.932 c
-6.009 5.953 l
-4.989 5.953 l
-4.932 5.102 l
-4.57 3.097 -2.893 1.367 -.85 1.077 c
0 .964 l
f*
Q
q 1 0 0 1 552.189 373.209 cm 0 0 m
-.113 -1.02 l
-.29 -3.245 -2.749 -5.591 -4.932 -5.896 c
-5.953 -5.953 l
-5.953 -4.989 l
-5.102 -4.876 l
-3.097 -4.541 -1.371 -2.883 -1.077 -.85 c
-1.02 0 l
f*
Q
319.068 367.257 227.168 .96378 re
f
313.058 373.209 1.0205 37.871 re
f
551.168 373.209 1.0204 37.871 re
f
q 1 0 0 1 313.058 344.353 cm 0 0 m
.113 1.02 l
.561 3.385 2.535 5.556 4.989 5.839 c
6.009 5.953 l
6.009 4.989 l
5.159 4.876 l
3.116 4.586 1.44 2.856 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 546.236 350.305 cm 0 0 m
1.02 -.113 l
3.15 -.243 5.709 -2.802 5.839 -4.932 c
5.953 -5.953 l
4.932 -5.953 l
4.876 -5.102 l
4.573 -3.084 2.869 -1.38 .85 -1.077 c
0 -.964 l
f*
Q
319.068 349.342 227.168 .96378 re
f
q 1 0 0 1 319.068 225.298 cm 0 0 m
-1.02 .057 l
-3.657 .614 -5.338 2.295 -5.896 4.932 c
-6.009 5.953 l
-4.989 5.953 l
-4.932 5.102 l
-4.57 3.097 -2.893 1.367 -.85 1.077 c
0 .964 l
f*
Q
q 1 0 0 1 552.189 231.25 cm 0 0 m
-.113 -1.02 l
-.397 -3.474 -2.568 -5.449 -4.932 -5.896 c
-5.953 -5.953 l
-5.953 -4.989 l
-5.102 -4.876 l
-3.097 -4.541 -1.371 -2.882 -1.077 -.85 c
-1.02 0 l
f*
Q
319.068 225.298 227.168 .96381 re
f
313.058 231.25 1.0205 113.102 re
f
551.168 231.25 1.0204 113.102 re
f
BT
/F7 1 Tf
7.4718 0 0 7.4718 62.022 700.2707 Tm
0 Tc
0 Tw
[(59.)-505.4(Gruber.)-310.3(Sublingual)-301.4(can)-9.2(nabidiol)-304.6(for)-302.8(anxiety.)-308.1(ClinicalTrials.gov.)]TJ
1.7224 -1.2064 TD
[(NCT02548559.)-311.4(Published)-307.5(2018.)-304.9(Accessed)-308.1(2018.)]TJ
-1.7224 -1.1988 TD
[(60.)-505.4(Khoury)-252.2(JM,)-253.2(Neves)-247.1(MCLD,)-256.6(Roque)-246.3(MAV,)-250.3(et)-255.4(al.)-248.3(Is)-248.6(there)-247.2(a)-249.4(role)-251.8(for)-249.7(cannabidiol)]TJ
1.7224 -1.1988 TD
[(in)-296.4(psych)-11.7(iatry?)-304.1(World)-302.9(J)-303.7(Biol)-303.8(Psychiatry.)-309.6(2019;20:1011)-15.5(16.)]TJ
-1.7224 -1.1988 TD
[(61)18.4(.)-493.5(A)0(l)21.1(t)0(e)17.7(m)0(u)15.8(s)-287.9(M,)-283.3(Sa)19.5(rva)28(iya)-273.2(N,)-285.2(Ne)17.8(il)17.9(l)-287(E)0(p)19.1(p)0(e)14.9(r)0(s)18.9(o)0(n)-280.4(C)0(.)-285.7(S)0(e)17.8(x)-285.6(di)17.1(ffe)27.3(re)17.7(nc)20.2(es)-288.7(in)-281.3(a)16.2(n)0(x)16(i)0(e)15.8(t)0(y)-279.9(a)0(n)21.8(d)]TJ
1.692 -1.1988 TD
[(de)22.5(pre)25.8(ss)16.1(io)18.8(n)-282.6(c)0(l)15.9(i)16.6(nic)21.6(al)-270.8(pe)22.5(rs)18.9(pe)14.9(ct)17.8(iv)17.5(es)22.4(.)-281(Fro)21.7(nt)-271.7(Ne)17.9(ur)20.8(oe)16.7(nd)21.4(oc)16.8(ri)19.9(no)15.6(l.)-272.1(20)18.4(14)18.4(;3)16.5(5:)16.5(32)18.4(0)23.6(33)18.4(0.)]TJ
-1.692 -1.1988 TD
[(62.)-505.4(Donner)-230.8(NC,)-229.1(Lowry)-233.9(CA.)-235.6(Sex)-229.9(differences)-236.8(in)-228.1(anxiety)-232(and)-228(emotional)-235.6(behavior.)]TJ
1.7224 -1.2064 TD
[(Pugers)-303.9(Arch)-9.9(.)-296.2(2013;465)-11.7(:601626.)]TJ
-1.7224 -1.1988 TD
[(63.)-505.4(Green)-303.6(T,)-300.4(Flash)-301.6(S,)-308(Reiss)-302.2(AL.)-301.7(Sex)-305.8(differences)-305.1(in)-304(psychiatric)-313.1(disorders:)-307.6(what)]TJ
1.7224 -1.1988 TD
[(we)-303.7(can)-297.5(learn)-308.1(from)-304.5(sex)-301.1(chromosome)-307.2(aneuplo)-10.5(idies.)-300.9(Neuropsy)-13.7(chophar-)]TJ
T*
[(macology.)-311.2(2019;44:921.)]TJ
-1.7224 -1.1988 TD
[(64.)-505.4(Li)-297(SH,)-307.9(Graham)-301.7(BM.)-303.8(Wh)-8.7(y)-298.3(are)-300(women)-305(so)-300.8(vulner)-9.9(able)-301.4(to)-297.9(anxiet)-9.5(y,)-298.6(trauma-)]TJ
1.7224 -1.1988 TD
[(related)-280.4(and)-273.6(stress-related)-282.4(diso)-10.6(rders?)-273.5(The)-280(potential)-277.9(role)-282.2(of)-275.8(sex)-270.8(hormo)-10.9(nes.)]TJ
T*
[(Lancet)-305(Psychiatry.)-309.6(2017;4:73)-12.8(82.)]TJ
-1.7224 -1.2064 TD
[(65.)-505.4(McLean)-303(CP,)-301(Asnaa)-10.1(ni)-296.4(A,)-306.8(Litz)-299.2(BT,)-305.7(et)-301(al.)-301.4(Gender)-303.1(differences)-312.7(in)-304(anxiety)-300.2(dis-)]TJ
1.7224 -1.1988 TD
[(orders:)-279.6(prevalence,)-278.9(course)-273.9(of)-275.8(illness,)-271.2(comorbidi)-13.5(ty)-272.3(and)-266(burden)-276.8(of)-275.8(illness.)-278.7(J)]TJ
T*
[(Psychiatr)-306.8(Res.)-304.3(2011;45:1027)-14.7(1035.)]TJ
-1.7224 -1.1988 TD
[(66.)-505.4(Vesga-Lopez)-306.6(O,)-292.1(Schne)-9.5(ier)-292(FR,)-303(Wang)-298(S,)-300.4(et)-293.4(al.)-301.4(Gender)-303.1(differences)-305.1(in)-296.4(gener-)]TJ
1.7224 -1.1988 TD
[(alized)-305.6(anxiety)-300.2(disorder:)-308(result)-12.8(s)-295.5(from)-304.5(the)-302.9(National)-306.9(Epidemi)-10.5(ologic)-298.8(Survey)]TJ
T*
[(on)-303.1(Alcohol)-301.8(and)-303.9(Related)-306.6(Conditions)-308(\(NESARC\).)-308.5(J)-303.7(Clin)-299.7(Psychiatry.)-309.6(2008;69:)]TJ
0 -1.2064 TD
(16061616.)Tj
-1.7224 -1.1988 TD
[(67.)-505.4(Jalnapurkar)-309.6(I,)-302.4(Allen)-298.9(M,)-306.1(Pigott)-302.9(T.)-300.4(Sex)-305.7(differences)-312.7(in)-296.4(anxiety)-307.8(disorders:)-307.6(a)]TJ
1.7224 -1.1988 TD
[(review.)-306.7(J.)-296.4(Psy)-9.7(chiatry)-307.1(Depress)-304.5(Anxiety.)-304.5(2018;4:12.)]TJ
-1.7224 -1.1988 TD
[(68.)-505.4(Pigott)-257.3(TA.)-257.9(Anxiety)-258.7(disorders)-261.8(in)-250.9(women)-9.1(.)-250.7(Psy)-9.7(chiatr)-251.6(Cli)-9.5(n)-252.3(North)-255.1(Am.)-255.3(2003;26)-13.3(:)]TJ
1.7224 -1.1988 TD
[(621672,)-310(vivii.)]TJ
-1.7224 -1.1988 TD
[(69.)-505.4(Pigott)-302.9(TA.)-303.4(Gender)-303.1(differences)-312.7(in)-304(the)-302.9(epidemiology)-309(and)-303.9(treatment)-302(of)]TJ
1.7224 -1.2064 TD
[(anxiety)-307.8(disorders.)-307.6(J)-303.7(Clin)-299.7(Psychiatry.)-309.6(1999;60\(Sup)-14.5(pl.)-301.9(18\):415.)]TJ
-1.7224 -1.1988 TD
[(70.)-505.4(Cooper)-308.2(ZD,)-302.2(Craft)-305.5(RM.)-298.6(Sex-dep)-11.1(endent)-305.1(effects)-304.3(of)-298.6(canna)-10.1(bis)-301.2(and)-303.9(cannabi-)]TJ
1.7224 -1.1988 TD
[(noids:)-301.1(a)-302.5(translational)-310.4(perspec)-12.7(tive.)-298.9(Neuropsy)-13.7(chopharmacology.)-308.6(2018;43)-13.3(:)]TJ
T*
(3451.)Tj
-1.7224 -1.1988 TD
[(71.)-505.4(Nadulski)-303.2(T,)-308(Pragst)-305.1(F,)-302.8(Weinberg)-302.9(G,)-303.7(et)-301(al.)-301.4(Randomized)-12(,)-296.2(double-)-10.6(blind,)]TJ
1.7224 -1.1988 TD
[(placebo-controll)-16.4(ed)-296.2(study)-307(about)-309.3(the)-302.9(effects)-304.3(of)-298.6(can)-9.2(nabidiol)-304.6(\(CBD\))-301.9(on)-303.1(the)]TJ
T*
[(pharmacokinetics)-314.2(of)-298.6(Delta9-t)-11(etrahydrocannab)-16.2(inol)-300.4(\(THC\))-304.2(after)-301.6(oral)-303.2(appli)-10.5(-)]TJ
0 -1.2064 TD
[(cation)-305.7(of)-298.6(THC)-304.7(verses)-307.5(standardized)-307.4(canna)-10.1(bis)-301.2(extract.)-306.8(Ther)-299.5(Drug)-303.9(Mon)-9.5(it.)]TJ
0 -1.1988 TD
(2005;27:799810.)Tj
-1.7224 -1.1988 TD
[(72.)-505.4(Klumpers)-303.4(LE,)-310.4(Cole)-297.7(DM,)-302.6(Khalil)-9.7(i-Mahani)-298.9(N,)-307.9(et)-301(al.)-301.4(Manipulating)-307(brain)-306.8(con-)]TJ
1.7224 -1.1988 TD
[(nectivity)-306.6(with)-300.1(delta)-9.8(\(9\)-tetrahydrocannabi)-18.6(nol:)-302(a)-302.5(pharmacological)-310.1(resting)]TJ
T*
[(state)-303.8(FMRI)-303.6(study.)-307.3(Neuroimage.)-310.5(2012;63:17011711)-16.6(.)]TJ
-1.7224 -1.1988 TD
[(73.)-505.4(Spindle)-306.6(TR,)-300.5(Cone)-301(EJ,)-308.2(Schlienz)-300.6(NJ,)-308.1(et)-301(al.)-301.4(Acute)-302.4(pharmacok)-13.8(inetic)-300.8(prole)-308(of)]TJ
1.7224 -1.2064 TD
[(smoked)-305.2(and)-303.9(vaporized)-307.5(cannabis)-303.7(in)-304(human)-305.7(blood)-304.2(and)-303.9(oral)-303.2(uid.)-303.2(J)-296.1(Anal)]TJ
0 -1.1988 TD
[(Toxicol.)-306.2(2019;43:2332)-15.5(58.)]TJ
-1.7224 -1.1988 TD
[(74.)-505.4(M)20.5(a)16.2(t)18.5(h)0(e)35.3(s)15.6(o)17.5(n)-191.6(J)15(M)0(S)31.4(B)17.5(,)-190(D)18.6(i)-195.9(C)18.1(i)16.5(a)16.2(n)20.9(o)-195(P)22.6(,)-197.6(F)16.2(a)23.7(re)32.9(s)-196.8(A)19.8(,)-190(e)0(t)-179.6(a)23.7(l)16.5(.)-190(Se)33(x)-194.5(d)15.7(i)16.5(f)17.9(f)17.8(e)22(re)32.9(nc)35.4(es)-174.9(i)16.5(n)-191.6(th)31.8(e)-190.5(a)16.2(c)14.5(u)17.5(t)18.5(e)-190.5(ef)32.2(f)17.9(e)22(c)14.5(t)18.5(s)]TJ
1.7224 -1.1988 TD
-.0176 Tc
[(of)-303.3(s)5.6(m)-17.6(o)13.4(k)-17.6(e)17.1(d)-305.4(can)-17.6(n)16.5(abis)5.6(:)-306.2(e)4.4(viden)-17.6(c)10.2(e)-299.1(f).2(rom)-300(a)-304.9(hum)-17.6(a)12.1(n)-300.2(l)-1.1(a)6.1(b)-1.9(or)-17.6(a)17.1(t)-17.6(o)10.8(r).9(y)-300.8(s)-2(tudy)-300.8(of)-303.3(youn)-17.6(g)]TJ
T*
-.0171 Tc
[(adul)7(t)-17.1(s)9.4(.)-298.1(P)-2.1(s)6.1(y)-17.1(c)10.1(h)3.8(ophar)-17.1(m)14.9(acology)-17.1(.)-285.4(2019;)-298.1(DO)-17.1(I)11.1(:)-298.1(10.)5.4(1007/)-17.1(s)12.8(00213-019-)-17.1(0)21(5369-)-17.1(y)16.9(.)]TJ
-1.7224 -1.1988 TD
0 Tc
[(75.)-505.4(Onaivi)-304.2(ES,)-304.6(Chaudhuri)-308.9(G,)-296.2(Aba)-9.1(ci)-295.2(AS,)-303.4(et)-308.6(al.)-301.4(Expression)-306.9(of)-298.6(can)-9.2(nabinoid)-300.3(re-)]TJ
1.7224 -1.1988 TD
[(ceptors)-310.3(and)-296.3(their)-305.8(gene)-301.3(transcri)-12.6(pts)-299.2(in)-304(human)-305.7(blood)-304.2(cells.)-302.1(Progress)-311.7(Neu-)]TJ
0 -1.2064 TD
[(ropsychopharma)-16.8(col)-300.5(Biol)-303.8(Psychiatry.)-309.6(1999;23:1063)-14.7(1077.)]TJ
-1.7224 -1.1988 TD
[(76.)-505.4(Normandin)-304.7(MD,)-302.6(Zheng)-304.3(MQ,)-302(Lin)-306.5(KS,)-298.1(et)-308.6(al.)-301.4(Imaging)-299.6(the)-302.9(cannab)-9.6(inoid)-299.9(CB1)]TJ
1.7224 -1.1988 TD
[(receptor)-308.2(in)-296.4(hum)-8.9(ans)-304(with)-300.1([11C]OMAR:)-306.1(assessment)-310.2(of)-306.1(kinetic)-303.3(analysis)]TJ
T*
[(methods,)-309.2(test-retest)-305.1(reproducibi)-16.4(lity,)-300.2(and)-303.9(gender)-305.1(differences.)-313(J)-296.1(Cer)-9.7(eb)]TJ
T*
[(Blood)-302.4(Flow)-305.9(Metab.)-302.1(2015;35:)-13.6(13131322.)]TJ
-1.7224 -1.1988 TD
[(77.)-505.4(Neumeister)-308.5(A,)-299.2(Normandin)-312.3(MD,)-302.6(Pietrzak)-303.4(RH,)-303.9(et)-301(al.)-301.4(Eleva)-9.3(ted)-300.5(brain)-299.2(can)-9.2(na-)]TJ
1.7224 -1.2064 TD
[(binoid)-299.4(CB1)-296.7(receptor)-300.6(availabili)-11.5(ty)-295(in)-296.4(post-traumatic)-308.1(stress)-296.3(disorder:)-308(a)-294.9(posi-)]TJ
0 -1.1988 TD
[(tron)-304.1(emission)-309.6(tomography)-306.3(study.)-307.3(Mol)-302.2(Psychiatry.)-309.6(2013;18:)-13.6(10341040.)]TJ
31.8753 63.6064 TD
[(78.)-505.4(Van)-260.8(Laere)-257.7(K,)-256(Gof)-10.2(n)-255.8(K,)-256(Casteels)-265.3(C,)-255.3(et)-263(al.)-255.9(Gender-dependen)-13.4(t)-254.7(increases)-263.2(with)]TJ
1.7224 -1.2064 TD
[(healthy)-304.9(aging)-299.3(of)-298.6(the)-295.3(hum)-8.9(an)-296.8(cerebral)-303.9(cannabinoid-typ)-13.7(e)-296.7(1)-294.3(receptor)-308.2(bind-)]TJ
0 -1.1988 TD
[(ing)-305.9(using)-303.2([\(18\)F]MK-9470)-308.5(PET.)-304.7(Neuroima)-11.6(ge.)-298.9(2008;39:1533)-14.7(1541.)]TJ
-1.7224 -1.1988 TD
[(79.)-505.4(Cooper)-270.2(ZD,)-271.9(Haney)-269.7(M.)-268.1(Investigation)-271.9(of)-268.2(sex-dependen)-11.4(t)-262.2(effects)-273.9(of)-268.2(cannab)-9.6(is)]TJ
1.7224 -1.1988 TD
[(in)-304(daily)-301.7(cannab)-9.6(is)-301.7(smokers.)-302.2(Drug)-304(Alcohol)-309.4(Depend.)-302.8(2014;13)-13.3(6:8591.)]TJ
-1.7224 -1.1988 TD
[(80.)-505.4(Wardle)-229.1(MC,)-227.3(Marcus)-231.2(BA,)-228.7(de)-227.9(Wit)-222.2(H.)-227.9(A)-223(prelimina)-10.6(ry)-226.7(investigation)-233.9(of)-222.7(individual)]TJ
1.7224 -1.1988 TD
[(differences)-312.7(in)-296.4(subject)-13.9(ive)-301.9(responses)-307.2(to)-297.9(D-amphet)-12.8(amine,)-298.2(alcoho)-10.9(l,)-302.4(and)]TJ
0 -1.2064 TD
[(delta-9-)-11.2(tetrahydrocannabinol)-313.3(using)-303.2(a)-302.5(within-subjects)-315.7(randomized)-304.4(trial.)]TJ
0 -1.1988 TD
[(PLoS)-308(One.)-302.4(2015;10:e0140501)-18.2(.)]TJ
-1.7224 -1.1988 TD
[(81.)-505.4(Fogel)-301.6(JS,)-308.2(Kelly)-301.7(TH,)-307.9(Westgate)-305.8(PM,)-298.6(et)-301(al.)-309(Sex)-298.2(differences)-312.7(in)-296.4(the)-302.9(subjecti)-12.6(ve)]TJ
1.7224 -1.1988 TD
[(effects)-258.7(of)-260.6(oral)-250.1(delta)-9.8(\(9\)-THC)-258.6(in)-250.9(cannabis)-258.2(users.)-260.2(Pharmacol)-261.1(Biochem)-257.1(Behav.)]TJ
T*
[(2017;152)-11.7(:4451.)]TJ
-1.7224 -1.1988 TD
[(82.)-505.4(Roser)-306(PGJ,)-304.1(Weinberg)-310.5(G,)-296.2(Juckel)-311.6(G,)-303.7(et)-301(al.)-301.4(Psychomotor)-311.6(performance)-311.4(in)-296.4(re-)]TJ
1.7224 -1.1988 TD
[(lation)-303.7(to)-305.5(acute)-306(oral)-303.2(administration)-312.5(of)-298.6(Delta9-t)-11(etrahydrocannabi)-14.9(nol)-301.8(and)]TJ
0 -1.2064 TD
[(standa)-10.9(rdized)-304.1(cannabis)-303.7(extract)-306.5(in)-304(healthy)-304.9(human)-305.7(subjects.)-309.7(Eur)-302.1(Arch)-305.8(Psy-)]TJ
0 -1.1988 TD
[(chiatry)-307.1(Clin)-307.3(Neurosci.)-307.3(2009:284292.)]TJ
-1.7224 -1.1988 TD
[(8)-13.5(3)-13.5(.)-508.6(W)-14.4(i)0(e)-22.2(r)-11.9(s)-310.6(C)-12.2(E,)-315.6(S)-11.8(h)-9.5(o)-12.9(k)-10(r)-11.9(i)-13.8(-)-9.1(K)-12.9(o)-12.9(j)0(o)-16.7(r)-11.8(i)-309.7(E)-11.8(,)-311.4(W)-14.4(o)-12.9(n)-9.5(g)-305.4(C)-12.2(T)-11.8(,)-311.4(e)-8.4(t)-315.4(al)-20.4(.)-311.4(C)-12.2(an)-16.1(n)-17.1(a)0(b)-21.3(i)0(s)-316.9(a)-14.2(bu)-20(s)-14.7(e)-8.4(r)-11.9(s)-310.6(sh)-24.2(ow)]TJ
1.7527 -1.1988 TD
[(h)-9.5(y)-10(p)-14.7(o)-12.9(f)-12.5(r)-11.9(on)-14.8(t)-11.9(a)-14.2(li)-20(t)-11.9(y)-283.2(a)-14.2(n)-9.5(d)-287.8(b)-14.7(lu)-19.1(n)-9.5(t)-11.9(e)-8.4(d)-287.8(b)-14.6(r)-11.9(ai)-20.4(n)-282.6(r)-11.9(e)-16(s)0(p)-21.8(o)0(n)-22.4(s)0(e)-15.5(s)-287.9(t)-11.9(o)-293.6(a)-287.3(s)0(t)-19(i)-13.8(m)-9.2(u)-12.9(la)-20.4(n)-9.5(t)-285(c)-15.8(h)-9.5(al)-20.4(le)-22.2(n)-9.5(g)-9.5(e)-289.1(in)]TJ
T*
[(f)-12.5(e)-8.4(m)-16.8(a)0(l)-20.4(e)-8.4(s)-310.6(b)0(u)-20(t)-315.4(n)-9.5(o)-12.9(t)-307.8(i)-13.8(n)-305.4(m)-16.8(al)-20.4(e)-8.4(s)0(.)-318.5(N)-11.7(e)-16(u)0(r)-17.2(o)-12.9(p)-14.7(s)0(y)-17.2(c)-15.8(h)-9.5(o)-12.9(ph)-16.6(a)-14.2(r)-11.9(m)-9.2(a)-14.2(co)-21.2(lo)-19.1(g)-9.5(y)-10(.)-311.4(2)-13.5(0)-13.5(1)0(6)-19.5(;)0(4)-21.4(1)-13.5(:2)-21.4(59)-19.5(6)-13.5()]TJ
T*
.0135 Tc
[(26)13.5(0)-6(5)0(.)]TJ
-1.7527 -1.2064 TD
0 Tc
[(84.)-505.4(Khan)-296.5(SS,)-297(Secades-Villa)-298.8(R,)-288.7(Okud)-10.7(a)-287.3(M)0(,)-290.9(e)0(t)-293.4(al.)-293.9(Gender)-295.5(differences)-305.1(in)-288.8(cannab)-9.6(is)]TJ
1.7224 -1.1988 TD
[(use)-278.8(diso)-10.6(rders:)-281.8(results)-278(fr)-9.2(om)-272.5(the)-280.1(National)-284.1(Epidemi)-10.5(ologic)-276(Survey)-289.2(of)-275.8(Alcohol)]TJ
T*
[(and)-303.9(Related)-306.6(Conditions.)-308.3(Drug)-303.9(Alcohol)-309.4(Depend.)-302.8(2013;130)-11.7(:101108.)]TJ
-1.7224 -1.1988 TD
[(85.)-505.4(Cuttler)-310.6(C,)-300.9(Mischley)-308.4(LK,)-304(Sexton)-302.1(M.)-306.1(Sex)-298.2(differences)-312.7(in)-296.4(can)-9.2(nabis)-302.1(use)-301.6(and)]TJ
1.7224 -1.1988 TD
[(effects:)-259(a)-249.4(cross-secti)-14.8(onal)-247.7(survey)-254.2(of)-253(cannabis)-258.2(users.)-252.6(Cannabis)-254.6(Cannabino)-11.9(id)]TJ
T*
[(Res.)-304.3(2016;1:16617)-15.5(5.)]TJ
-1.7224 -1.2064 TD
[(86.)-505.4(Herrm)-10.9(ann)-298.7(ES,)-304.6(Weerts)-304.8(EM,)-302.7(Vandrey)-305.7(R.)-303.9(Sex)-298.2(differences)-312.7(in)-304(cannabis)-303.7(with-)]TJ
1.7224 -1.1988 TD
[(drawal)-303.4(sy)-9.6(mptoms)-300.3(am)-8.2(ong)-297.4(treatment)-13.7(-seeking)-303.4(cannabis)-303.7(users.)-305.7(Exp)-304.5(Clin)]TJ
T*
[(Psychophar)-14.7(macol.)-301.5(2015;23:415)-16.3(421.)]TJ
-1.7224 -1.1988 TD
[(87.)-505.4(Millar)-305(SA,)-303.4(Stone)-304.8(NL,)-302.8(Yates)-307.3(AS,)-303.4(et)-301(al.)-301.4(A)-298.9(systematic)-314.4(review)-298.8(on)-303.1(the)-302.9(pharma-)]TJ
1.7224 -1.1988 TD
[(cokineti)-12.7(cs)-296.2(of)-306.1(cannabidiol)-306.3(in)-304(humans.)-305.6(Front)-303.1(Pharmaco)-12(l.)-294.8(2018;9:1)-13.6(365.)]TJ
/F4 1 Tf
-.7815 -3.7331 TD
[(Cite)-301.7(this)-306(article)-307(as:)]TJ
/F7 1 Tf
8.5663 0 TD
[(Wright)-306.1(M,)-306.1(Di)-298.7(Ciano)-305.5(P,)-303.9(Brands)-305.5(B)-301.2(\(2019\))-304.1(Use)-303.8(of)]TJ
-8.5663 -1.1988 TD
[(cannabidiol)-306.3(for)-302.8(the)-302.9(treatment)-309.6(of)-298.6(anxiety:)-308.1(a)-302.5(short)-303.7(synthesis)-304.6(of)-306.2(pre-)]TJ
T*
[(clinical)-254.8(and)-258.4(clinical)-254.8(evidence)-9.7(,)]TJ
/F11 1 Tf
12.2691 0 TD
[(Cannabis)-257.9(and)-257.6(Cannabinoid)-267(Research)]TJ
/F7 1 Tf
15.1068 0 TD
(5:3,)Tj
-27.3759 -1.2064 TD
[(191196,)-302.4(DOI:)-302.4(10.1089/c)-14.9(an.2019.0052.)]TJ
/F4 1 Tf
8.9663 0 0 8.9663 393.1652 336.4724 Tm
[(Abbreviations)-336.5(Used)]TJ
/F7 1 Tf
7.4718 0 0 7.4718 334.2613 324.17 Tm
(5-HT1A)Tj
/F12 1 Tf
3.2323 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(5-hydroxytryptamine)-318.1(1A)]TJ
-2.7391 -1.1988 TD
(CB1)Tj
/F12 1 Tf
1.7982 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(cannabinoid)-301.9(type)-310.5(1)]TJ
-2.8833 -1.2064 TD
(CBD)Tj
/F12 1 Tf
1.9424 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
(cannabidiol)Tj
-2.9364 -1.1988 TD
(EPM)Tj
/F12 1 Tf
1.9955 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(elevated)-298.7(plus)-10.6(-maze)]TJ
-3.4447 -1.1988 TD
(FAAH)Tj
/F12 1 Tf
2.5039 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(fatty)-303.3(acid)-301.3(amide)-303.1(hydrola)-11.1(se)]TJ
-3.0198 -1.1988 TD
(GAD)Tj
/F12 1 Tf
2.079 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(generalized)-300.1(anxiet)-9.5(y)-298.3(disorder)]TJ
-3.0274 -1.1988 TD
(OCD)Tj
/F12 1 Tf
2.0866 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(obsessive-compulsive)-316.9(disorder)]TJ
-3.2778 -1.1988 TD
(PTSD)Tj
/F12 1 Tf
2.337 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(post-traumatic)-308.1(stress)-311.5(disorder)]TJ
-2.8605 -1.1988 TD
(SAD)Tj
/F12 1 Tf
1.9196 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(social)-297.8(an)-8.5(xiety)-299.3(disorder)]TJ
-2.8226 -1.2064 TD
(THC)Tj
/F12 1 Tf
1.8817 0 TD
()Tj
/F10 1 Tf
.9409 0 TD
(D)Tj
/F7 1 Tf
.6601 0 TD
[(-9-)-9(tetrahydrocannabinol)]TJ
-4.3856 -1.1988 TD
(TRPV1)Tj
/F12 1 Tf
2.7846 0 TD
()Tj
/F7 1 Tf
.9409 0 TD
[(transient)-303(receptor)-308.2(potential)-12.3(,)-296.2(vanilloid)-310.4(type)-302.9(1)-301.9(receptor)]TJ
/F4 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(196)Tj
42.4515 0 TD
[(WRIGH)-11.1(T)-301.2(E)0(T)-299.4(AL.)]TJ
ET
endstream
endobj
55 0 obj
<>stream
hbd`ad`ddvL)0q6q57+i ^!FR :"~|WXtesWnXr)R'5f+jjXؾJnUi
'뒗HO4n}vµsp6yA%ݭ|?t~[tּ+kf./=Kǫa3!25^@df p]`
endstream
endobj
57 0 obj
<>stream
hTP1n0
2lxu]hW@M <'E#wll N`dFpew<(%蠮%:Gg6Ȗ&8\w$_4`p}WC2ܗ3xM; bbq,qwg*LW._#$sK|w>y7 di
endstream
endobj
60 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
63 0 obj
<>stream
IPPOFI+AdvPi1 R/ AdvPi1 % W.rU T!U!x\;ٙIi.
endstream
endobj
66 0 obj
<>stream
hTQMo +|!MNBt>tSp2 B#~{ƆhMC6<-N"\pX JKF閣@pNGH]a}q)t9s ox(i@aOEW1"OWP'0
} ?Gqp$WE0C9VW,k]~ x!>OQ7WY\ų\|k\mn8V#kC~
endstream
endobj
65 0 obj
<>stream
h\mPWw6?t+":ٴjGA m
Q*MABD+54Ӣ8E*_:m3]ٹ3s=1/bDE:&01iMx=! lиg<ߥ͵6,.zqp\W&հ9i0&C-WEZ"W+奫5j"#@R 5,VQh٢D)پP^$Lv:6$61}2ŰX/Lc8&`1̛>_:\r|8R> qp
ܟ/grHM?;h*?}!B߄:}ɸ@]Qrc"\%cvh!m|!Qv SfM})exb/e:q3yKVnmeR93ؚdCh߃)ۃh;-M-@qhC}!k<~lL'/C>'L0$}Z: <-?d$!L+}WI8Mpc ǭ[7-IF+|yRhICʠ,彿@\ }:]ee*-Q,"?\6G{Ic]p0Fh
AWF=>35$k\C39bM{c8Yf1փF}V-h3-s&7n]6"PhtD>ŇMC?ߡ
22 b'RM:S1>OGwNbwR$S"g3GZ$?уH"`F`
nnvW1m{yZmYP*CuA&K]ƢNPbi[D{
bczEJirÏr
#. !Z0#^@jZ-fDԣRbʸKw w.|ɐ(ş G7#fUeUxLbLDi))^,a]P#̛͔wi_Cr;wtcERY{ڠU4R.}zLP`3aq"Yj5Ym=.S~s iqZ]\j